PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22468731-3 2012 The label for rosiglitazone was revised in November 2007 to include the warning of contraindicated use with nitrates or insulin, creating an opportunity for a PA directed at safe use. Rosiglitazone 14-27 insulin Homo sapiens 120-127 24577463-2 2014 Inconclusive results have been reported in clinical trials of rosiglitazone, an insulin sensitizer that also increases cardiovascular mortality risks. Rosiglitazone 62-75 insulin Homo sapiens 80-87 24094981-9 2013 This hypothesis could explain why rosiglitazone is superior to metformin in enhancement of insulin sensitivity. Rosiglitazone 34-47 insulin Homo sapiens 91-98 24117256-6 2013 In contrast, in long-term obesity, insulin resistance and (or) hyperinsulinemia result in the down-regulation of CSE and H2S deficiency, which is corrected by treatment with the insulin sensitizer rosiglitazone. Rosiglitazone 197-210 insulin Homo sapiens 35-42 24117256-6 2013 In contrast, in long-term obesity, insulin resistance and (or) hyperinsulinemia result in the down-regulation of CSE and H2S deficiency, which is corrected by treatment with the insulin sensitizer rosiglitazone. Rosiglitazone 197-210 insulin Homo sapiens 68-75 23913730-7 2013 Interestingly, FTO mRNA levels were increased in SAT of type 2 diabetic patients, and treatment of diabetics with Rosiglitazone improved insulin sensitivity and reduced SAT FTO mRNA levels. Rosiglitazone 114-127 insulin Homo sapiens 137-144 22582808-8 2012 Up-regulation of Sfrp5 expression and secretion in adipocytes may be one crucial mechanism by which rosiglitazone and metformin improve insulin sensitivity. Rosiglitazone 100-113 insulin Homo sapiens 136-143 22592687-0 2012 Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Rosiglitazone 38-51 insulin Homo sapiens 0-7 24492466-8 2014 Moreover, the insulin-sensitising peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, rosiglitazone, significantly increased adipolin protein expression and secretion in subcutaneous adipose tissue explants (P<0.05 and P<0.01). Rosiglitazone 104-117 insulin Homo sapiens 14-21 23991629-0 2013 Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant alpha-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus. Rosiglitazone 86-99 insulin Homo sapiens 66-73 23593417-0 2013 Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial. Rosiglitazone 37-50 insulin Homo sapiens 112-119 23593417-2 2013 We aimed to determine if adding rosiglitazone to rhGH would abrogate the adverse effects of rhGH on insulin sensitivity (SI) and subcutaneous adipose tissue (SAT) volume. Rosiglitazone 32-45 insulin Homo sapiens 100-107 23593417-13 2013 CONCLUSIONS/SIGNIFICANCE: The addition of rosiglitazone abrogated the adverse effects of rhGH on insulin sensitivity and glucose tolerance while not significantly modifying the lowering effect of rhGH on VAT. Rosiglitazone 42-55 insulin Homo sapiens 97-104 24029780-1 2013 BACKGROUND: Thiazolidinediones (TZDs) - rosiglitazone and pioglitazone - a class of insulin sensitizer for treating type 2 diabetes, have been reported to exhibit neuroprotective effects in preclinical studies and have good effects in the control of blood sugar for diabetic patients with insulin resistance. Rosiglitazone 40-53 insulin Homo sapiens 84-91 24029780-1 2013 BACKGROUND: Thiazolidinediones (TZDs) - rosiglitazone and pioglitazone - a class of insulin sensitizer for treating type 2 diabetes, have been reported to exhibit neuroprotective effects in preclinical studies and have good effects in the control of blood sugar for diabetic patients with insulin resistance. Rosiglitazone 40-53 insulin Homo sapiens 289-296 23983807-0 2013 Electroacupuncture and rosiglitazone combined therapy as a means of treating insulin resistance and type 2 diabetes mellitus: a randomized controlled trial. Rosiglitazone 23-36 insulin Homo sapiens 77-84 23081744-6 2013 In vitro, treatment of adipocytes with rosiglitazone, an insulin sensitizer that binds to peroxisome proliferator-activated receptor (PPAR) receptors and increases the adipocyte response to insulin, significantly increased the expression of the antidiabetic adipokine adiponectin. Rosiglitazone 39-52 insulin Homo sapiens 57-64 23081744-6 2013 In vitro, treatment of adipocytes with rosiglitazone, an insulin sensitizer that binds to peroxisome proliferator-activated receptor (PPAR) receptors and increases the adipocyte response to insulin, significantly increased the expression of the antidiabetic adipokine adiponectin. Rosiglitazone 39-52 insulin Homo sapiens 190-197 22847059-2 2012 This study aimed to determine whether the insulin-sensitising peroxisome proliferator-activated receptor gamma (PPARgamma) activator rosiglitazone affects adipose tissue vascularisation in normal humans. Rosiglitazone 133-146 insulin Homo sapiens 42-49 22374753-1 2012 Rosiglitazone is a thiazolidinedione, a synthetic PPARgamma receptor agonist with insulin-sensitizing properties that is used as an antidiabetic drug. Rosiglitazone 0-13 insulin Homo sapiens 82-89 21970545-12 2012 Fasting insulin levels significantly declined after rosiglitazone therapy (p < 0.001) without change in glucose levels this resulted in normalization of the mean glucose to insulin ratio. Rosiglitazone 52-65 insulin Homo sapiens 8-15 21970545-12 2012 Fasting insulin levels significantly declined after rosiglitazone therapy (p < 0.001) without change in glucose levels this resulted in normalization of the mean glucose to insulin ratio. Rosiglitazone 52-65 insulin Homo sapiens 176-183 21970545-13 2012 CONCLUSIONS: Short term administration of rosiglitazone to overweight and obese PCOS women results in enhancement of CC induced ovulation as well as improvement of insulin sensitivity. Rosiglitazone 42-55 insulin Homo sapiens 164-171 22468731-9 2012 RESULTS: At 30 days, there were 134 patients (60.4% of 222) in the comparison group with concurrent supply of rosiglitazone with insulin and/or nitrates versus 4 patients (2.4% of 168, P less than 0.001) in the PA intervention group, and the utilization rate remained significantly higher at 180 days in the comparison group (37.8%, n = 84) versus the PA group (2.4%, n = 4, P less than 0.001). Rosiglitazone 110-123 insulin Homo sapiens 129-136 22036866-4 2012 Insulin sensitizers (such as rosiglitazone and pioglitazone) inhibit inflammation while improving insulin sensitivity. Rosiglitazone 29-42 insulin Homo sapiens 0-7 22036866-4 2012 Insulin sensitizers (such as rosiglitazone and pioglitazone) inhibit inflammation while improving insulin sensitivity. Rosiglitazone 29-42 insulin Homo sapiens 98-105 22424623-6 2012 Delta value of homeostasis model assessment of beta cell function (HOMA-B) and Delta value of fasting proinsulin levels were statistically significant between three genotype groups (P=0.0149 and 0.0246, respectively) after rosiglitazone treatment. Rosiglitazone 223-236 insulin Homo sapiens 102-112 21576196-0 2011 Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin. Rosiglitazone 0-13 insulin Homo sapiens 90-97 22473412-0 2012 Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study. Rosiglitazone 26-39 insulin Homo sapiens 103-110 22654727-5 2011 This is currently being attempted with drugs such as the insulin sensitizer rosiglitazone. Rosiglitazone 76-89 insulin Homo sapiens 57-64 22028424-6 2011 Because of this, rosiglitazone and pioglitazone have been evaluated as potential treatments for AD because of their insulin-sensitizing and antiinflammatory effects. Rosiglitazone 17-30 insulin Homo sapiens 116-123 21709296-4 2011 RESULTS: Glycemic parameters and insulin sensitivity improved in the rosiglitazone/metformin arm in year 1, but deteriorated in the years thereafter as in the placebo arm. Rosiglitazone 69-82 insulin Homo sapiens 33-40 21483233-3 2012 Rosiglitazone is used as a drug to improve insulin sensitivity in vivo. Rosiglitazone 0-13 insulin Homo sapiens 43-50 21424914-11 2011 In the rosiglitazone group, FPG, PPG, HbA1c, insulin, HOMA-IR, IL-6, and TNF-alpha levels decreased significantly after 12 weeks compared with the basal levels. Rosiglitazone 7-20 insulin Homo sapiens 45-52 21576196-7 2011 These results show that, in patients with advanced T2DM treated with insulin, addition of rosiglitazone may have a beneficial effect on endothelial function. Rosiglitazone 90-103 insulin Homo sapiens 69-76 21415383-4 2011 RESULTS: Measures of beta-cell function and insulin sensitivity from an OGTT showed more favorable changes over time with rosiglitazone versus metformin or glyburide. Rosiglitazone 122-135 insulin Homo sapiens 44-51 21463620-13 2011 Our results suggested that supplementing diabetic patients receiving insulin treatment with adjunct therapy of rosiglitazone may have some benefit for controlling diabetic complications. Rosiglitazone 111-124 insulin Homo sapiens 69-76 20832829-8 2011 Rosiglitazone significantly increased adipocyte reesterification and improved insulin sensitivity, but the potential benefit of these changes was compromised by increase in total lipolysis. Rosiglitazone 0-13 insulin Homo sapiens 78-85 21666815-1 2011 Rosiglitazone is a synthetic agonist of peroxisome proliferator-activated receptor gamma which is used to improve insulin resistance in patients with type II diabetes. Rosiglitazone 0-13 insulin Homo sapiens 114-121 21666815-2 2011 Rosiglitazone exerts its glucose-lowering effects by improving insulin sensitivity. Rosiglitazone 0-13 insulin Homo sapiens 63-70 21666815-3 2011 Data from various studies in the past decade suggest that the therapeutic effects of rosiglitazone reach far beyond its use as an insulin sensitizer since it also has other benefits on the cardiovascular system such as improvement of contractile dysfunction, inhibition of the inflammatory response by reducing neutrophil and macrophage accumulation, and the protection of myocardial injury during ischemic/reperfusion in different animal models. Rosiglitazone 85-98 insulin Homo sapiens 130-137 21559208-0 2011 Rosiglitazone-Mediated Effects on Skeletal Muscle Gene Expression Correlate with Improvements in Insulin Sensitivity in Individuals with HIV-Insulin Resistance. Rosiglitazone 0-13 insulin Homo sapiens 97-104 21325466-8 2011 Compared with drospirenone/EE, treatment with rosiglitazone improved hepatic and peripheral insulin sensitivity and lowered fasting and stimulated insulin levels during the oral glucose tolerance test. Rosiglitazone 46-59 insulin Homo sapiens 92-99 21325466-8 2011 Compared with drospirenone/EE, treatment with rosiglitazone improved hepatic and peripheral insulin sensitivity and lowered fasting and stimulated insulin levels during the oral glucose tolerance test. Rosiglitazone 46-59 insulin Homo sapiens 147-154 21559208-1 2011 Rosiglitazone, an agonist of peroxisome proliferator activated receptor (PPARgamma), improves insulin sensitivity by increasing insulin-stimulated glucose uptake into muscle tissue. Rosiglitazone 0-13 insulin Homo sapiens 94-101 21559208-1 2011 Rosiglitazone, an agonist of peroxisome proliferator activated receptor (PPARgamma), improves insulin sensitivity by increasing insulin-stimulated glucose uptake into muscle tissue. Rosiglitazone 0-13 insulin Homo sapiens 128-135 21559208-2 2011 This study was undertaken to assess changes in expression of PPAR-regulated genes in muscle tissue following treatment of HIV-associated insulin resistance with rosiglitazone. Rosiglitazone 161-174 insulin Homo sapiens 137-144 21559208-5 2011 The HIV-IR group"s rosiglitazone-mediated improvement in insulin sensitivity was highly correlated with increased expression of PPARgamma and carnitine palmitoyl transferase-1 (CPT-1), (r = 0.87, P < .001) and (r = 0.95, P < .001), respectively. Rosiglitazone 19-32 insulin Homo sapiens 57-64 21559208-7 2011 The results suggest that rosiglitazone; may have a direct effect on muscle tissue to improve insulin sensitivity. Rosiglitazone 25-38 insulin Homo sapiens 93-100 21040499-7 2011 RESULTS: Rosiglitazone treatment reduced insulin resistance and partially restored beta-cell mass in animals with reduced beta-cell mass at birth. Rosiglitazone 9-22 insulin Homo sapiens 41-48 21368750-0 2011 Preserved response to diuretics in rosiglitazone-treated subjects with insulin resistance: a randomized double-blind placebo-controlled crossover study. Rosiglitazone 35-48 insulin Homo sapiens 71-78 21040499-8 2011 The addition of metformin to rosiglitazone decreased insulin resistance and reduced weight gain, but had no additional effect on beta-cell mass. Rosiglitazone 29-42 insulin Homo sapiens 53-60 21040499-10 2011 Although the combination of rosiglitazone and metformin did not affect beta-cell mass at 26 weeks of age, it did result in reduced body weight and insulin resistance. Rosiglitazone 28-41 insulin Homo sapiens 147-154 21040499-11 2011 CONCLUSION: The results of the present study suggest that the addition of metformin to rosiglitazone improves the metabolic profile through an effect on insulin resistance and not beta-cell mass. Rosiglitazone 87-100 insulin Homo sapiens 153-160 20682614-10 2011 Rosiglitazone eliminated glucose- and insulin-induced increase in oxLDL phagocytosis in all studied groups. Rosiglitazone 0-13 insulin Homo sapiens 38-45 21167254-0 2011 Rosiglitazone balances insulin-induced exo- and endocytosis in single 3T3-L1 adipocytes. Rosiglitazone 0-13 insulin Homo sapiens 23-30 21167254-1 2011 Rosiglitazone (Rosi) improves insulin sensitivity and increases the translocation of glucose transporter 4 (GLUT4) to the plasma membrane (PM). Rosiglitazone 0-13 insulin Homo sapiens 30-37 21167254-1 2011 Rosiglitazone (Rosi) improves insulin sensitivity and increases the translocation of glucose transporter 4 (GLUT4) to the plasma membrane (PM). Rosiglitazone 0-4 insulin Homo sapiens 30-37 21167254-7 2011 We conclude that Rosi-pretreatment balances insulin-stimulated exocytosis and endocytosis, which may prevent insulin-mediated adipocyte cell size increase. Rosiglitazone 17-21 insulin Homo sapiens 44-51 21167254-7 2011 We conclude that Rosi-pretreatment balances insulin-stimulated exocytosis and endocytosis, which may prevent insulin-mediated adipocyte cell size increase. Rosiglitazone 17-21 insulin Homo sapiens 109-116 21430606-12 2011 CONCLUSIONS: Rosiglitazone treatment in patients with NAFLD is safe, well-tolerated and leads to a significant improvement in liver function and insulin sensitivity, without adversely affecting the lipid profile. Rosiglitazone 13-26 insulin Homo sapiens 145-152 21031343-12 2011 CONCLUSIONS: Both rosiglitazone/metformin combination therapy and metformin monotherapy decreased serum vaspin levels through glucose and insulin sensitivity regulation, while they exerted differential effects on adiponectin, IL-6 and other cardiovascular risk factors in drug-naive patients with T2DM. Rosiglitazone 18-31 insulin Homo sapiens 138-145 19233878-5 2011 DBT displays the characteristic of rosiglitazone by increasing the whole-body insulin sensitivity in fructose chow-fed rats after 2-week treatment, as evidenced by the marked elevation of composite whole-body insulin sensitivity index during the oral glucose tolerance test. Rosiglitazone 35-48 insulin Homo sapiens 78-85 20929990-8 2011 Triple therapy (rosiglitazone, metformin, and any insulin) resulted in a greater reduction in A1C than rosiglitazone plus insulin (-0.50 +- 0.14%, P < 0.001) and metformin plus insulin (-0.45 +- 0.14%, P < 0.001). Rosiglitazone 103-116 insulin Homo sapiens 50-57 20947819-8 2011 CONCLUSIONS: Rosiglitazone improved insulin sensitivity and decreased postprandial hydroxybutyric acid levels in patients with HIV-lipodystrophy, suggesting improved FFA handling. Rosiglitazone 13-26 insulin Homo sapiens 36-43 20943749-7 2011 Interestingly, rosiglitazone treatment improved insulin sensitivity and reduced FTO expression in muscle from type 2 diabetic patients. Rosiglitazone 15-28 insulin Homo sapiens 48-55 21672339-1 2011 Metformin and rosiglitazone combination therapy is known to improve insulin resistance and postpone diabetes mellitus development in subjects with impaired glucose tolerance. Rosiglitazone 14-27 insulin Homo sapiens 68-75 21672339-0 2011 Effects of metformin and rosiglitazone on peripheral insulin resistance and beta-cell function in obesity: a double-blind, randomized, controlled study. Rosiglitazone 25-38 insulin Homo sapiens 53-60 21672339-5 2011 Metformin plus rosiglitazone significantly decreased blood pressure, lipids, BMI, and fasting and postmeal insulin levels. Rosiglitazone 15-28 insulin Homo sapiens 107-114 21672339-8 2011 The metformin and rosiglitazone combination increased insulin sensitivity and beta-cell function recovered. Rosiglitazone 18-31 insulin Homo sapiens 54-61 20923486-2 2010 The concomitant use of nitrates, renin-angiotensin system (RAS) blockers, or insulin has been linked to a potential increase in myocardial ischemic risk with rosiglitazone. Rosiglitazone 158-171 insulin Homo sapiens 77-84 20971975-5 2011 Rosiglitazone significantly reduced fasting insulin and high-sensitivity C-reactive protein (hsCRP) and increased apoA-II levels. Rosiglitazone 0-13 insulin Homo sapiens 44-51 20863714-3 2010 Long-term use of rosiglitazone, a synthetic PPARgamma agonist and a drug to treat insulin resistance, increases fracture rates among patients with diabetes. Rosiglitazone 17-30 insulin Homo sapiens 82-89 20356610-0 2011 What is the effect of rosiglitazone treatment on insulin secretory function in insulin-resistant individuals? Rosiglitazone 22-35 insulin Homo sapiens 49-56 20356610-0 2011 What is the effect of rosiglitazone treatment on insulin secretory function in insulin-resistant individuals? Rosiglitazone 22-35 insulin Homo sapiens 79-86 20356610-2 2011 The goal of this study was to compare methods used to quantify the effect of rosiglitazone (RSG) on insulin secretory function, particularly estimates based on changes in fasting plasma glucose and insulin concentration vs daylong insulin responses to meals. Rosiglitazone 77-90 insulin Homo sapiens 100-107 20356610-2 2011 The goal of this study was to compare methods used to quantify the effect of rosiglitazone (RSG) on insulin secretory function, particularly estimates based on changes in fasting plasma glucose and insulin concentration vs daylong insulin responses to meals. Rosiglitazone 92-95 insulin Homo sapiens 100-107 20356610-7 2011 Insulin sensitivity improved (P < .001) after RSG administration, with decreases of 31% +- 23% and 21% +- 14% in steady-state plasma glucose concentration in nondiabetic and diabetic subjects, respectively. Rosiglitazone 49-52 insulin Homo sapiens 0-7 20356610-8 2011 Although fasting and daylong plasma glucose and insulin concentrations fell (P < .001) in both groups of RSG-treated individuals, HOMA-beta decreased in nondiabetic subjects and did not change in those with 2DM. Rosiglitazone 108-111 insulin Homo sapiens 48-55 20356610-9 2011 In conclusion, RSG administration improved insulin sensitivity in both groups, associated with lower fasting and daylong glucose concentrations. Rosiglitazone 15-18 insulin Homo sapiens 43-50 20356610-10 2011 Fasting and daylong insulin concentrations were also lower in both groups of RSG-treated subjects, but the values of HOMA-beta indicated either a decrease (nondiabetics) or no change (diabetics) in insulin secretory function. Rosiglitazone 77-80 insulin Homo sapiens 20-27 20356610-10 2011 Fasting and daylong insulin concentrations were also lower in both groups of RSG-treated subjects, but the values of HOMA-beta indicated either a decrease (nondiabetics) or no change (diabetics) in insulin secretory function. Rosiglitazone 77-80 insulin Homo sapiens 198-205 20467418-3 2011 We tested, in a pilot study, whether rosiglitazone (ROSI) restores normal glucose tolerance (NGT) in obese adolescents with IGT by improving insulin sensitivity and beta-cell function. Rosiglitazone 37-50 insulin Homo sapiens 141-148 20467418-3 2011 We tested, in a pilot study, whether rosiglitazone (ROSI) restores normal glucose tolerance (NGT) in obese adolescents with IGT by improving insulin sensitivity and beta-cell function. Rosiglitazone 52-56 insulin Homo sapiens 141-148 20467418-9 2011 ROSI restores NGT by increasing peripheral insulin sensitivity and beta-cell function, two principal pathophysiological abnormalities of IGT. Rosiglitazone 0-4 insulin Homo sapiens 43-50 20528570-5 2010 The thiazolidinediones rosiglitazone and pioglitazone were recently applied as insulin sensitising treatment in patients with PCOS. Rosiglitazone 23-36 insulin Homo sapiens 79-86 20499046-0 2010 Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage. Rosiglitazone 36-49 insulin Homo sapiens 78-85 20499046-13 2010 CONCLUSIONS/INTERPRETATION: Rosiglitazone may increase vascular leakage in insulin-treated patients with type 2 diabetes with autonomic neuropathy. Rosiglitazone 28-41 insulin Homo sapiens 75-82 20573187-7 2010 Rosiglitazone modestly improved fasting insulin (WMD -3.67 mU/L; CI -7.03, -0.31) but worsened triglycerides (WMD 32.5 mg/dL; CI 1.93, 63.1), LDL (WMD 11.33 mg/dL; CI 1.85, 20.82) and HDL (WMD -2.91 mg/dL; CI -4.56, -1.26) when compared to placebo or no treatment in seven trials. Rosiglitazone 0-13 insulin Homo sapiens 40-47 20105179-1 2010 BACKGROUND AND PURPOSE: Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists, such as rosiglitazone and pioglitazone, sensitize cells to insulin, and are therefore used to treat type 2 diabetes. Rosiglitazone 103-116 insulin Homo sapiens 154-161 20026082-10 2010 We conclude that in adipocytes, rosiglitazone increases cell surface GLUT4 levels by increasing its endosomal recycling and restores insulin-induced GLUT4 translocation in insulin resistance. Rosiglitazone 32-45 insulin Homo sapiens 133-140 20026082-10 2010 We conclude that in adipocytes, rosiglitazone increases cell surface GLUT4 levels by increasing its endosomal recycling and restores insulin-induced GLUT4 translocation in insulin resistance. Rosiglitazone 32-45 insulin Homo sapiens 172-179 20026082-11 2010 These results implicate novel modes of action on GLUT4 that are all likely to contribute to the insulin-sensitizing effect of rosiglitazone in type 2 diabetes. Rosiglitazone 126-139 insulin Homo sapiens 96-103 20415685-10 2010 Insulin sensitizers, including pioglitazone and rosiglitazone, and lipid-lowering agents, including statins and fibrates, also upregulate adiponectin and ameliorate liver histology. Rosiglitazone 48-61 insulin Homo sapiens 0-7 20229808-6 2010 Several studies have shown that insulin sensitizers (pioglitazone and rosiglitazone) improve cognition and memory in patients with mild Alzheimer disease as well as animal model of Alzheimer disease. Rosiglitazone 70-83 insulin Homo sapiens 32-39 20191245-0 2010 Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Rosiglitazone 0-13 insulin Homo sapiens 61-68 19850645-2 2010 The importance of PPARgamma is accentuated by the widespread use of synthetic PPARgamma agonists, thiazolidinediones (such as rosiglitazone), as drugs for insulin resistance and type II diabetes. Rosiglitazone 126-139 insulin Homo sapiens 155-162 19765783-3 2010 Here, we examined if acute exposure to rosiglitazone stimulates glucose transport rate and affects proximal insulin signaling in isolated skeletal muscle strips from nondiabetic men. Rosiglitazone 39-52 insulin Homo sapiens 108-115 20158097-1 2010 Peroxisome proliferator-activated receptor gamma (PPARgamma) plays critical roles on insulin sensitivity and adipocyte differentiation, and therefore, several agonists such as pioglitazone and rosiglitazone are used as anti-diabetic drugs. Rosiglitazone 193-206 insulin Homo sapiens 85-92 20091537-0 2010 Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Rosiglitazone 38-51 insulin Homo sapiens 0-7 20158101-4 2010 Indeed, pioglitazone and rosiglitazone, ligands for PPARgamma, improve insulin resistance in diabetic patients, and now become one of the most popular anti-diabetic drugs in the developed countries. Rosiglitazone 25-38 insulin Homo sapiens 71-78 20158105-3 2010 Pharmacologic treatment with thiazolidinedions, such as rosiglitazone and pioglitazone, agonists of the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma), may offer some therapeutic relief of AD by lowering peripheral insulin and enhancing insulin sensitivity. Rosiglitazone 56-69 insulin Homo sapiens 246-253 20158105-3 2010 Pharmacologic treatment with thiazolidinedions, such as rosiglitazone and pioglitazone, agonists of the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma), may offer some therapeutic relief of AD by lowering peripheral insulin and enhancing insulin sensitivity. Rosiglitazone 56-69 insulin Homo sapiens 268-275 19911850-1 2010 Rosiglitazone is a thiazolidinedione used to treat insulin resistance in diabetes. Rosiglitazone 0-13 insulin Homo sapiens 51-58 20121886-0 2010 The effect of rosiglitazone on insulin sensitivity and mid-thigh low-density muscle in patients with Type 2 diabetes. Rosiglitazone 14-27 insulin Homo sapiens 31-38 20121886-5 2010 RESULTS: Twelve weeks" rosiglitazone treatment resulted in improved insulin resistance despite increases in body weight and BMI. Rosiglitazone 23-36 insulin Homo sapiens 68-75 20121886-9 2010 CONCLUSIONS: Rosiglitazone treatment resulted in an improvement of insulin responsiveness in Type 2 diabetic subjects, which was associated with the redistribution of visceral and subcutaneous adipose tissue, an increase in TLDMA, and changes in serum adipocytokine levels. Rosiglitazone 13-26 insulin Homo sapiens 67-74 20121886-10 2010 Further studies are needed to elucidate the insulin sensitizing mechanism of rosiglitazone on peripheral skeletal muscles. Rosiglitazone 77-90 insulin Homo sapiens 44-51 21686295-2 2010 Rosiglitazone is an insulin-sensitizing agent used to control blood glucose levels in patients with type 2 diabetes. Rosiglitazone 0-13 insulin Homo sapiens 20-27 19556978-9 2010 Such orchestrated changes in expression of multiple proteins provide insights into the mechanism underlying the increased efficiency in glucose uptake and improvement of insulin sensitivity in response to rosiglitazone treatment. Rosiglitazone 205-218 insulin Homo sapiens 170-177 19338578-5 2009 Therefore, the effect of PPARgamma and PPARgamma ligands like rosiglitazone on insulin gene transcription was investigated. Rosiglitazone 62-75 insulin Homo sapiens 79-86 19533082-11 2009 Furthermore, rosiglitazone significantly increased basal and insulin-stimulated glucose uptake when podocytes were treated with the NEFA palmitate. Rosiglitazone 13-26 insulin Homo sapiens 61-68 19821299-0 2009 Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Rosiglitazone 38-51 insulin Homo sapiens 0-7 24683246-0 2009 Effectiveness and tolerability of rosiglitazone on insulin resistance and body composition in nondiabetic Thai patients undergoing continuous ambulatory peritoneal dialysis: A 12-week pilot study. Rosiglitazone 34-47 insulin Homo sapiens 51-58 24683246-2 2009 OBJECTIVE: The aim of this study was to investigate the effectiveness and tolerability of rosiglitazone on insulin resistance and body composition in patients without diabetes mellitus (DM) undergoing CAPD. Rosiglitazone 90-103 insulin Homo sapiens 107-114 24683246-16 2009 CONCLUSIONS: Rosiglitazone 2 mg BID for 12 weeks was associated with significantly improved insulin resistance in this small group of nondiabetic Thai patients undergoing CAPD. Rosiglitazone 13-26 insulin Homo sapiens 92-99 19338578-10 2009 Also in normal primary pancreatic islets of transgenic mice, known to express high levels of PPARgamma, rosiglitazone inhibited glucose-stimulated insulin gene transcription. Rosiglitazone 104-117 insulin Homo sapiens 147-154 19338578-8 2009 KEY RESULTS: Rosiglitazone caused a PPARgamma-dependent inhibition of insulin gene transcription in a beta-cell line. Rosiglitazone 13-26 insulin Homo sapiens 70-77 19338578-11 2009 Transactivation and mapping experiments suggest that, in contrast to the rat glucagon gene, the inhibition of the human insulin gene promoter by PPARgamma/rosiglitazone does not depend on promoter-bound Pax6 and is attributable to the proximal insulin gene promoter region around the transcription start site from -56 to +18. Rosiglitazone 155-168 insulin Homo sapiens 120-127 19338578-11 2009 Transactivation and mapping experiments suggest that, in contrast to the rat glucagon gene, the inhibition of the human insulin gene promoter by PPARgamma/rosiglitazone does not depend on promoter-bound Pax6 and is attributable to the proximal insulin gene promoter region around the transcription start site from -56 to +18. Rosiglitazone 155-168 insulin Homo sapiens 244-251 19322744-7 2009 Rosiglitazone improved peripheral insulin sensitivity (+36.7+/-15.7 ml/min/m (2), p=0.03, means+/-SEM), while no change was observed in P (+4.5+/-19.5 ml/min/m (2), p=0.55). Rosiglitazone 0-13 insulin Homo sapiens 34-41 19322744-12 2009 Rosiglitazone treatment resulted in improved peripheral insulin sensitivity with increased circulating adiponectin in HIV patients under HAART. Rosiglitazone 0-13 insulin Homo sapiens 56-63 19368716-14 2009 Lower endotoxin and higher adiponectin in the groups treated with RSG may be related and indicate another mechanism for the effect of RSG on insulin sensitivity. Rosiglitazone 66-69 insulin Homo sapiens 141-148 19776322-0 2009 Rosiglitazone effects to ameliorate Alzheimer"s disease pathogenic features: insulin signaling and neurotrophic factors. Rosiglitazone 0-13 insulin Homo sapiens 77-84 19183127-1 2009 OBJECTIVE: The primary purpose of this 8-week double-blind, placebo-controlled trial of rosiglitazone 4 mg/day was to examine its effect on insulin sensitivity index (SI) and glucose utilization (SG) in clozapine-treated subjects with schizophrenia with insulin resistance. Rosiglitazone 88-101 insulin Homo sapiens 140-147 19183127-1 2009 OBJECTIVE: The primary purpose of this 8-week double-blind, placebo-controlled trial of rosiglitazone 4 mg/day was to examine its effect on insulin sensitivity index (SI) and glucose utilization (SG) in clozapine-treated subjects with schizophrenia with insulin resistance. Rosiglitazone 88-101 insulin Homo sapiens 254-261 19183127-5 2009 CONCLUSION: Rosiglitazone may have a role in addressing insulin resistance and lipid abnormalities associated with clozapine. Rosiglitazone 12-25 insulin Homo sapiens 56-63 19405411-10 2009 Rosiglitazone and pioglitazone are also effective for ameliorating hirsutism and insulin resistance. Rosiglitazone 0-13 insulin Homo sapiens 81-88 19368716-14 2009 Lower endotoxin and higher adiponectin in the groups treated with RSG may be related and indicate another mechanism for the effect of RSG on insulin sensitivity. Rosiglitazone 134-137 insulin Homo sapiens 141-148 19449752-4 2009 Thiazolidinediones, in particular of the rosiglitazone type, have a positive impact on increased tissue sensitivity to insulin built on the activation of PPAR-gamma. Rosiglitazone 41-54 insulin Homo sapiens 119-126 19449763-2 2009 At the beginning of the therapy, metformin is used; later, insulin sensitizers (PPAR-gamma stimulators) such as rosiglitazone and pioglitazone are often applied. Rosiglitazone 112-125 insulin Homo sapiens 59-66 19283231-4 2009 DISCUSSION: Pioglitazone and rosiglitazone can be employed as oral therapy in patients with type 2 diabetes and preserved endogenous insulin secretion. Rosiglitazone 29-42 insulin Homo sapiens 133-140 19217454-7 2009 In conclusion, RSG and PIO appear to have comparable abilities to improve insulin sensitivity and lower daylong glucose, insulin, and FFA concentrations in nondiabetic, insulin-resistant individuals. Rosiglitazone 15-18 insulin Homo sapiens 74-81 19217454-7 2009 In conclusion, RSG and PIO appear to have comparable abilities to improve insulin sensitivity and lower daylong glucose, insulin, and FFA concentrations in nondiabetic, insulin-resistant individuals. Rosiglitazone 15-18 insulin Homo sapiens 121-128 19217454-7 2009 In conclusion, RSG and PIO appear to have comparable abilities to improve insulin sensitivity and lower daylong glucose, insulin, and FFA concentrations in nondiabetic, insulin-resistant individuals. Rosiglitazone 15-18 insulin Homo sapiens 121-128 19188609-8 2009 At submaximal insulin doses, protection was potentiated by rosiglitazone, an insulin-sensitizing drug used to treat type 2 diabetes. Rosiglitazone 59-72 insulin Homo sapiens 14-21 19188609-8 2009 At submaximal insulin doses, protection was potentiated by rosiglitazone, an insulin-sensitizing drug used to treat type 2 diabetes. Rosiglitazone 59-72 insulin Homo sapiens 77-84 21299185-1 2009 BACKGROUND: Thiazolidinediones (rosiglitazone and pioglitazone) whether administered alone or in combination with metformin, sulfonylurea, or insulin, are often accompanied by an increase in weight and/or plasma volume. Rosiglitazone 32-45 insulin Homo sapiens 142-149 18991162-2 2009 In this study, rosiglitazone was used in the clinical treatment of insulin resistance in patients with type 2 diabetes mellitus. Rosiglitazone 15-28 insulin Homo sapiens 67-74 19839823-2 2009 Rosiglitazone (ROS) improves insulin sensitivity in the liver, muscle, and adipose tissue. Rosiglitazone 0-13 insulin Homo sapiens 29-36 19839823-2 2009 Rosiglitazone (ROS) improves insulin sensitivity in the liver, muscle, and adipose tissue. Rosiglitazone 15-18 insulin Homo sapiens 29-36 18476983-0 2008 Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Rosiglitazone 0-13 insulin Homo sapiens 49-56 19475776-2 2009 Rosiglitazone, a drug in the thiazolidinedione class which targets insulin resistance, was approved by drug regulatory bodies based on its ability to improve glycemic control nearly ten years ago. Rosiglitazone 0-13 insulin Homo sapiens 67-74 19097138-2 2008 HYPOTHESIS: The purpose of the study was to analyze the effects of rosiglitazone, an insulin sensitizer agent, on cardiac morphometry and functioning. Rosiglitazone 67-80 insulin Homo sapiens 85-92 19033001-1 2008 BACKGROUND: Rosiglitazone, a thiazolidinedione, has effects on insulin sensitivity and cardiovascular risk factors that may favorably impact the progression of coronary atherosclerosis. Rosiglitazone 12-25 insulin Homo sapiens 63-70 19033001-2 2008 METHODS: APPROACH is a double-blind randomized clinical trial comparing the effects of the insulin sensitizer rosiglitazone with the insulin secretagogue glipizide on the progression of coronary atherosclerosis. Rosiglitazone 110-123 insulin Homo sapiens 91-98 18476983-8 2008 CONCLUSIONS: Rosiglitazone and pioglitazone have similar beneficial effects on glycaemic control insulin sensitivity, insulin secretion and plasma adipocytokine levels. Rosiglitazone 13-26 insulin Homo sapiens 97-104 19011089-6 2008 DsbA-L expression in 3T3-L1 adipocytes is stimulated by the insulin sensitizer rosiglitazone and inhibited by the inflammatory cytokine TNFalpha. Rosiglitazone 79-92 insulin Homo sapiens 60-67 18812026-3 2008 The results showed that BFOV, similar to vanadyl sulfate and rosiglitazone, caused a concentration-dependent increase in glucose consumption by insulin-resistant adipocytes. Rosiglitazone 61-74 insulin Homo sapiens 144-151 17825080-6 2008 The pharmacological tools available to improve insulin sensitivity include the biguanides (metformin) and thiazolidinediones (rosiglitazone and pioglitazone). Rosiglitazone 126-139 insulin Homo sapiens 47-54 18254722-0 2008 Importance of the high-molecular-mass isoform of adiponectin in improved insulin sensitivity with rosiglitazone treatment in HIV disease. Rosiglitazone 98-111 insulin Homo sapiens 73-80 18254722-1 2008 The present study was designed to investigate the relationship of isoforms of adiponectin to insulin sensitivity in subjects with HIV-associated insulin resistance in response to treatment with the thiazolidinedione, rosiglitazone. Rosiglitazone 217-230 insulin Homo sapiens 145-152 18254722-5 2008 Treatment with rosiglitazone for 3 months resulted in a significant improvement in the index of hepatic insulin sensitivity (86.4+/-15% compared with 139+/-23; P=0.007) as well as peripheral insulin sensitivity (4.04+/-0.23 compared with 6.17+/-0.66 mg of glucose/kg of lean body mass per min; P<0.001). Rosiglitazone 15-28 insulin Homo sapiens 104-111 18254722-7 2008 The present study suggests that the HMW isoform of adiponectin is important in the regulation of rosiglitazone-mediated improvement in insulin sensitivity in individuals with HIV-associated insulin resistance, particularly in the liver. Rosiglitazone 97-110 insulin Homo sapiens 135-142 18254722-7 2008 The present study suggests that the HMW isoform of adiponectin is important in the regulation of rosiglitazone-mediated improvement in insulin sensitivity in individuals with HIV-associated insulin resistance, particularly in the liver. Rosiglitazone 97-110 insulin Homo sapiens 190-197 18583261-0 2008 [Effects of rosiglitazone on inflammatory reaction and insulin resistance in obese patients with newly diagnosed type 2 diabetes]. Rosiglitazone 12-25 insulin Homo sapiens 55-62 18541328-0 2008 The effect of rosiglitazone on oxidative stress and insulin resistance in overweight individuals. Rosiglitazone 14-27 insulin Homo sapiens 52-59 18541328-7 2008 Fasting plasma insulin concentrations decreased by 24% and HOMA increased by 35% in those receiving rosiglitazone. Rosiglitazone 100-113 insulin Homo sapiens 15-22 18541328-10 2008 Treatment with rosiglitazone also resulted in significantly reduced first phase (-33%) and second phase (-20%) insulin release. Rosiglitazone 15-28 insulin Homo sapiens 111-118 18541328-11 2008 CONCLUSIONS: In overweight non-diabetic people rosiglitazone reduces oxidative stress and improves insulin sensitivity. Rosiglitazone 47-60 insulin Homo sapiens 99-106 18466213-1 2008 OBJECTIVE: To evaluate the effect of rosiglitazone, an insulin sensitizer, on glycaemic control and insulin resistance in adolescents with type 1 diabetes mellitus (T1DM) RESEARCH DESIGN AND METHODS: Randomized, double-blind, placebo-controlled crossover trial of rosiglitazone (4 mg twice daily) vs. placebo (24 wk each, with a 4 wk washout period). Rosiglitazone 37-50 insulin Homo sapiens 55-62 18466213-1 2008 OBJECTIVE: To evaluate the effect of rosiglitazone, an insulin sensitizer, on glycaemic control and insulin resistance in adolescents with type 1 diabetes mellitus (T1DM) RESEARCH DESIGN AND METHODS: Randomized, double-blind, placebo-controlled crossover trial of rosiglitazone (4 mg twice daily) vs. placebo (24 wk each, with a 4 wk washout period). Rosiglitazone 37-50 insulin Homo sapiens 100-107 18492785-9 2008 Neither treatment demonstrated significant improvements in AN; however, rosiglitazone did significantly decrease serum insulin levels. Rosiglitazone 72-85 insulin Homo sapiens 119-126 17394563-5 2008 Rosiglitazone administration induced a significant decrease in glucose concentration (4.7 +/- 0.1 vs. 4.4 +/- 0.1 mmol/l, p < 0.005) and insulin-circulating level (13.6 +/- 1.5 vs. 8.0 +/- 0.,7 microU/ml, p < 0.005), an increase in insulin sensitivity as measured by homeostatic model assessment (HOMA) of insulin sensitivity (68.9 +/- 8.8 vs. 109.9 +/- 10.3, p < 0.005) with a concomitant decrease in beta-cell function as measured by HOMA of beta-cell function (163.2 +/- 16.1 vs. 127.4 +/- 8.4, p < 0.005). Rosiglitazone 0-13 insulin Homo sapiens 140-147 17394563-5 2008 Rosiglitazone administration induced a significant decrease in glucose concentration (4.7 +/- 0.1 vs. 4.4 +/- 0.1 mmol/l, p < 0.005) and insulin-circulating level (13.6 +/- 1.5 vs. 8.0 +/- 0.,7 microU/ml, p < 0.005), an increase in insulin sensitivity as measured by homeostatic model assessment (HOMA) of insulin sensitivity (68.9 +/- 8.8 vs. 109.9 +/- 10.3, p < 0.005) with a concomitant decrease in beta-cell function as measured by HOMA of beta-cell function (163.2 +/- 16.1 vs. 127.4 +/- 8.4, p < 0.005). Rosiglitazone 0-13 insulin Homo sapiens 238-245 17394563-5 2008 Rosiglitazone administration induced a significant decrease in glucose concentration (4.7 +/- 0.1 vs. 4.4 +/- 0.1 mmol/l, p < 0.005) and insulin-circulating level (13.6 +/- 1.5 vs. 8.0 +/- 0.,7 microU/ml, p < 0.005), an increase in insulin sensitivity as measured by homeostatic model assessment (HOMA) of insulin sensitivity (68.9 +/- 8.8 vs. 109.9 +/- 10.3, p < 0.005) with a concomitant decrease in beta-cell function as measured by HOMA of beta-cell function (163.2 +/- 16.1 vs. 127.4 +/- 8.4, p < 0.005). Rosiglitazone 0-13 insulin Homo sapiens 238-245 17394563-8 2008 CONCLUSION: Our study shows that in severely obese, non-diabetic, hyperinsulinaemic patients undergoing a nutritional programme, rosiglitazone is more effective than metformin in producing favourable changes in fasting-based indexes of glucose metabolism, with a reduction of both insulin resistance and hyperinsulinaemia. Rosiglitazone 129-142 insulin Homo sapiens 71-78 18322300-12 2008 CONCLUSIONS: A 6-month therapy with insulin sensitizers resulted in marked improvement in adipose tissue GLUT4 mRNA expression in PCOS patients, rosiglitazone being more effective when compared with metformin. Rosiglitazone 145-158 insulin Homo sapiens 36-43 18572037-4 2008 Insulin sensitivity improved significantly in the CRD- and RSG-treated groups, but to a greater extent in those administered RSG, without a significant difference comparing FEN treatment with the CRD. Rosiglitazone 59-62 insulin Homo sapiens 0-7 18572037-7 2008 Significant decreases in postprandial glucose and insulin were seen in only the RSG- and CRD-treated groups. Rosiglitazone 80-83 insulin Homo sapiens 50-57 18572037-8 2008 FEN administration improved dyslipidemia in these subjects without changing insulin sensitivity, whereas insulin sensitivity was enhanced in RSG-treated patients without improvement in dyslipidemia. Rosiglitazone 141-144 insulin Homo sapiens 105-112 18394743-0 2008 Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. Rosiglitazone 0-13 insulin Homo sapiens 23-30 18394743-10 2008 In conclusion, RSG improves the insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus, which is related to an increase in subcutaneous adiposity. Rosiglitazone 15-18 insulin Homo sapiens 32-39 18460571-0 2008 The insulin-sensitizing effect of rosiglitazone in type 2 diabetes mellitus patients does not require improved in vivo muscle mitochondrial function. Rosiglitazone 34-47 insulin Homo sapiens 4-11 18460571-1 2008 AIMS: Our objective was to investigate whether improved in vivo mitochondrial function in skeletal muscle and intramyocellular lipids (IMCLs) contribute to the insulin-sensitizing effect of rosiglitazone. Rosiglitazone 190-203 insulin Homo sapiens 160-167 18460571-5 2008 RESULTS: Insulin sensitivity improved after rosiglitazone (glucose infusion rate: 19.9 +/- 2.8 to 24.8 +/- 2.1 micromol/kg.min; P < 0.05). Rosiglitazone 44-57 insulin Homo sapiens 9-16 18460571-9 2008 CONCLUSION: The rosiglitazone-enhanced insulin sensitivity does not require improved muscular mitochondrial function. Rosiglitazone 16-29 insulin Homo sapiens 39-46 18583261-5 2008 RESULTS: In group A, rosiglitazone treatment resulted in significantly reduced serum hs-CRP, IL-1beta, IL-6, TNF-alpha, FPG and insulin resistance index (P<0.01). Rosiglitazone 21-34 insulin Homo sapiens 128-135 18583261-7 2008 CONCLUSION: Rosiglitazone can decrease FPG, reduce the inflammation reaction and improve insulin resistance in obese patients with type 2 diabetes. Rosiglitazone 12-25 insulin Homo sapiens 89-96 18285418-11 2008 CONCLUSION: These data indicate dissociation between the insulin-sensitizing effects of RSG and absence of anticipated reductions in production rates of apoB-100- and apoB-48-containing-TRL particles, which may explain the absence of TG lowering seen in humans treated with this agent. Rosiglitazone 88-91 insulin Homo sapiens 57-64 18375253-0 2008 Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. Rosiglitazone 0-13 insulin Homo sapiens 31-38 18054196-6 2008 Using the phosphatidylinositol 3-kinase inhibitor (PI3K inhibitor, LY 294002), we found that insulin inhibited the expression of AdipoR2 through the PI3K pathway and this inhibition was blocked by addition of rosiglitazone. Rosiglitazone 209-222 insulin Homo sapiens 93-100 18054196-7 2008 When porcine adipocytes were cultured without insulin, supplementation with 10 nM insulin inhibited the expression of AdipoR2 and this inhibition effect was also blocked by addition of rosiglitazone. Rosiglitazone 185-198 insulin Homo sapiens 46-53 18054196-7 2008 When porcine adipocytes were cultured without insulin, supplementation with 10 nM insulin inhibited the expression of AdipoR2 and this inhibition effect was also blocked by addition of rosiglitazone. Rosiglitazone 185-198 insulin Homo sapiens 82-89 18285418-0 2008 Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production. Rosiglitazone 55-68 insulin Homo sapiens 25-32 18285418-8 2008 RESULTS: RSG treatment resulted in significant insulin sensitization with no change in body weight. Rosiglitazone 9-12 insulin Homo sapiens 47-54 18346728-1 2008 The use of the thiazolidinedione insulin sensitizers rosiglitazone and pioglitazone for the treatment of type 2 diabetes mellitus in recent years has proven to be effective in helping patients resume normal glycemic control. Rosiglitazone 53-66 insulin Homo sapiens 33-40 18346728-8 2008 Treatment of obese Zucker rats with either rosiglitazone or SPPARgammaM5 resulted in an improvement in selected parameters that serve as surrogate indicators of insulin resistance and hyperlipidemia. Rosiglitazone 43-56 insulin Homo sapiens 161-168 18328348-11 2008 However, it is important to determine whether the glucose-lowering effect of RSG occurs mainly through direct enhancement of insulin sensitivity. Rosiglitazone 77-80 insulin Homo sapiens 125-132 18191635-0 2008 Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression. Rosiglitazone 0-13 insulin Homo sapiens 54-61 18328348-1 2008 The objective of the study was to investigate the effects of rosiglitazone (RSG), a thiazolidinedione derivative, on body fat distribution and insulin sensitivity in Korean subjects with type 2 diabetes mellitus. Rosiglitazone 61-74 insulin Homo sapiens 143-150 18328348-1 2008 The objective of the study was to investigate the effects of rosiglitazone (RSG), a thiazolidinedione derivative, on body fat distribution and insulin sensitivity in Korean subjects with type 2 diabetes mellitus. Rosiglitazone 76-79 insulin Homo sapiens 143-150 18191635-2 2008 In the present study, we examined the effects of rosiglitazone (RGZ) on insulin release and synthesis in pancreatic beta-cell (INS-1). Rosiglitazone 49-62 insulin Homo sapiens 72-79 18332304-0 2008 Low-dose rosiglitazone in patients with type 2 diabetes mellitus requiring insulin therapy. Rosiglitazone 9-22 insulin Homo sapiens 75-82 30764090-4 2008 Drugs such as rosiglitazone, exercise and weight loss have been shown to decrease circulating RBP4 levels and improve insulin resistance, but contradictory results have been found in other studies. Rosiglitazone 14-27 insulin Homo sapiens 118-125 21221185-3 2008 Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Rosiglitazone 55-68 insulin Homo sapiens 74-81 18215356-9 2008 The RR homozygotes had a better response to rosiglitazone treatment in terms of insulin sensitivity improvement than minor K allele carriers. Rosiglitazone 44-57 insulin Homo sapiens 80-87 17956948-6 2008 RESULTS: During rosiglitazone, HbA(1c) decreased from 8.9 +/- 0.4% to 7.8 +/- 0.3% (P = 0.007) and insulin requirements from 218 +/- 22 to 129 +/- 20 IU/d (P = 0.002). Rosiglitazone 16-29 insulin Homo sapiens 99-106 18212130-1 2008 Convergent evidence has revealed an association between insulin resistance and Alzheimer"s disease (AD), and the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, rosiglitazone, an insulin sensitizer and mitochondrial activator, improves cognition in patients with early or mild-to-moderate AD. Rosiglitazone 184-197 insulin Homo sapiens 202-209 18095238-7 2008 The HbA (1c) reductions with RSG+MET, but not SU+MET, were accompanied by significant improvements in measures of beta-cell function including proinsulin:insulin ratio. Rosiglitazone 29-32 insulin Homo sapiens 146-153 17956948-0 2008 Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. Rosiglitazone 0-13 insulin Homo sapiens 36-43 18220486-6 2008 Rosiglitazone and pioglitazone resulted in a similar improvement in HbA1c and insulin sensitivity. Rosiglitazone 0-13 insulin Homo sapiens 78-85 19075761-5 2008 With the clinical success of the PPARgamma agonists, pioglitazone (Actos) and rosiglitazone (Avandia), development of novel and potent insulin-sensitizing agents with diverse clinical profiles has been accelerated. Rosiglitazone 78-91 insulin Homo sapiens 135-142 17956948-0 2008 Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. Rosiglitazone 0-13 insulin Homo sapiens 78-85 17956948-10 2008 CONCLUSIONS: Our results suggest that rosiglitazone may be particularly effective in type 2 diabetic patients who are poorly controlled despite using high insulin doses. Rosiglitazone 38-51 insulin Homo sapiens 155-162 18074413-0 2007 Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial. Rosiglitazone 10-23 insulin Homo sapiens 41-48 18048112-6 2007 Glimepiride stimulates the beta-cell secretion and leads to reduction of blood glucose values, rosiglitazone stimulates peroxisome proliferator-activated receptor-gamma and improves insulin resistance, at the vascular and metabolically active cells. Rosiglitazone 95-108 insulin Homo sapiens 182-189 18074413-1 2007 AIM: To evaluate and compare effects of 48-week treatment with rosiglitazone and metformin on insulin resistance in patients infected with Human Immunodeficiency Virus (HIV) receiving highly active antiretroviral therapy (HAART), containing a protease inhibitor. Rosiglitazone 63-76 insulin Homo sapiens 94-101 18074413-6 2007 RESULTS: After 48 weeks of treatment, the fasting insulin concentration (+/-standard deviation) in rosiglitazone group significantly declined from 39.0+/-3.35 to 19.7+/-3.99 mIU/L (P<0.001; 49% decrease) and in metformin group from 40.3+/-2.29 to 29.2+/-2.82 mIU/L (P<0.001; 27% decrease). Rosiglitazone 99-112 insulin Homo sapiens 50-57 18074413-7 2007 HOMA indicated that rosiglitazone significantly reduced insulin resistance from 11.3+/-1.03 to 4.0+/-0.95 (P<0.001), compared with metformin which reduced it from 11.9+/-0.73 to 5.7+/-0.62 (P<0.001). Rosiglitazone 20-33 insulin Homo sapiens 56-63 18074413-8 2007 Insulin resistance was significantly lower in the rosiglitazone group after 48 weeks (P<0.001). Rosiglitazone 50-63 insulin Homo sapiens 0-7 18074413-12 2007 Rosiglitazone significantly more reduced insulin resistance, while beta cell function was significantly better in patients on metformin. Rosiglitazone 0-13 insulin Homo sapiens 41-48 18074413-13 2007 Both drugs may be considered as an appropriate therapy, with rosiglitazone being a better alternative in treating insulin resistance in this patient population. Rosiglitazone 61-74 insulin Homo sapiens 114-121 17890427-10 2007 It remains to be determined whether longer-term insulin sensitization therapy with rosiglitazone will augment skeletal muscle mitochondrial bioenergetics in those diabetic subjects with relatively preserved basal aerobic capacity. Rosiglitazone 83-96 insulin Homo sapiens 48-55 18004308-4 2007 report that rosiglitazone, a thiazolidinedione insulin sensitizer and a potent peroxisome proliferator-activated receptor gamma agonist, not only effectively improves glycemic control but also halts progression of albuminuria in type 2 diabetic patients with early-stage diabetic nephropathy. Rosiglitazone 12-25 insulin Homo sapiens 47-54 17785501-9 2007 Insulin increased NPY secretion (control: 0.22 +/- 0.024 ng/ml; 1 nM insulin: 0.26 +/- 0.05 ng/ml; 100 nM insulin: 0.29 +/- 0.04 ng/ml; 1,000 nM insulin: 0.3 +/- 0.04 ng/ml; P < 0.05, n = 13), but cotreatment of RSG (10 nM) with insulin (100 nM) had no effect on NPY secretion. Rosiglitazone 215-218 insulin Homo sapiens 0-7 17890427-0 2007 A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in Type 2 diabetes mellitus. Rosiglitazone 17-30 insulin Homo sapiens 40-47 18048467-5 2007 Rosiglitazone significantly decreased C-peptide (p < 0.01) with a strong trend toward decreased fasting insulin (p = 0.05). Rosiglitazone 0-13 insulin Homo sapiens 107-114 17890427-5 2007 Rosiglitazone significantly ameliorated fasting glucose, insulin, and free fatty acid levels but did not augment the subjects" maximal oxygen consumption (Vo(2max)) or their skeletal muscle mitochondrial copy number. Rosiglitazone 0-13 insulin Homo sapiens 57-64 17889553-4 2007 The results showed that both GY3 and rosiglitazone significantly increased the lipid accumulating of 3T3-L1 adipocytes induced by isobutylmethylxanthine, dexamethasone and insulin mixture, but GY3 (not rosiglitazone) failed to increase the lipid accumulation when induced by insulin alone. Rosiglitazone 37-50 insulin Homo sapiens 172-179 17889553-4 2007 The results showed that both GY3 and rosiglitazone significantly increased the lipid accumulating of 3T3-L1 adipocytes induced by isobutylmethylxanthine, dexamethasone and insulin mixture, but GY3 (not rosiglitazone) failed to increase the lipid accumulation when induced by insulin alone. Rosiglitazone 37-50 insulin Homo sapiens 275-282 17889553-7 2007 Furthermore, both GY3 and rosiglitazone enhanced the adiponectin and insulin pathway proteins expression and adiponectin secretion in mature adipocytes, but only GY3 not rosiglitazone elevated gene expression of leptin and resistin. Rosiglitazone 26-39 insulin Homo sapiens 69-76 18038714-14 2007 However, metformin at a higher dose and in combination with rosiglitazone resulted in improvement of pancreatic beta-cell function, shown by markedly improved first-phase insulin response to glucose measured by AIR. Rosiglitazone 60-73 insulin Homo sapiens 171-178 17889553-8 2007 Both GY3 and rosiglitazone enhanced glucose consumption in HepG2 cells especially in the presence of insulin. Rosiglitazone 13-26 insulin Homo sapiens 101-108 17555498-1 2007 OBJECTIVE: The peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist rosiglitazone increases insulin sensitivity, which, in animal models, is comparable to the effect of a reduction in 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activity. Rosiglitazone 84-97 insulin Homo sapiens 108-115 17555498-2 2007 We therefore investigated whether rosiglitazone-induced insulin sensitivity is associated with changes in 11beta-HSD1 activity in different tissues. Rosiglitazone 34-47 insulin Homo sapiens 56-63 17555498-7 2007 RESULTS: As expected, rosiglitazone improved insulin resistance and postprandial hyperglycaemia. Rosiglitazone 22-35 insulin Homo sapiens 45-52 18038714-17 2007 CONCLUSION: We suggest that early initiation of combined therapy comprising a high dose of metformin plus rosiglitazone may be valuable in managing insulin resistance and DM2 in children with AS. Rosiglitazone 106-119 insulin Homo sapiens 148-155 17705694-8 2007 CONCLUSIONS: The results of the experiments indicate that the insulin sensitizer rosiglitazone cannot reverse all of the damage associated with diabetes to the autonomic nervous system, but much can be reversed. Rosiglitazone 81-94 insulin Homo sapiens 62-69 17310221-9 2007 Rosiglitazone significantly increased PGC-1 alpha ( approximately 2.2-fold, P<0.01) and PPAR beta/delta ( approximately 2.6-fold, P<0.01), in parallel with an increase in insulin sensitivity, SDH activity and metabolic flexibility (P<0.01). Rosiglitazone 0-13 insulin Homo sapiens 177-184 17654601-2 2007 Rosiglitazone, a selective ligand of peroxisome proliferator-activated receptor gamma (PPARgamma), is an insulin sensitizer drug that has been used in a number of insulin-resistant conditions, including NAFLD. Rosiglitazone 0-13 insulin Homo sapiens 105-112 17654601-2 2007 Rosiglitazone, a selective ligand of peroxisome proliferator-activated receptor gamma (PPARgamma), is an insulin sensitizer drug that has been used in a number of insulin-resistant conditions, including NAFLD. Rosiglitazone 0-13 insulin Homo sapiens 163-170 17310221-12 2007 CONCLUSION: These results suggest that the insulin-sensitizing effect of rosiglitazone may involve an effect on muscular oxidative capacity, via PGC-1 alpha and PPAR beta/delta, independent of mitochondrial protein content and/or changes in intramyocellular lipid. Rosiglitazone 73-86 insulin Homo sapiens 43-50 17486315-6 2007 RESULTS: The second phase of the insulin response was significantly decreased by rosiglitazone: 13,066 +/- 1,531 vs 16,316 +/- 2,813 pmol l(-1) 110 min in controls (p < 0.05), without change in the first phase. Rosiglitazone 81-94 insulin Homo sapiens 33-40 17636829-16 2007 No interventions influenced fasting C-peptide, but insulin maintained stimulated C-peptide better than SU (one study, mean difference 7.7 ng/ml (95% CI 2.9 to 12.5) and insulin with rosiglitazone was superior to insulin alone (one study) at maintaining stimulated C-peptide. Rosiglitazone 182-195 insulin Homo sapiens 169-176 17636829-16 2007 No interventions influenced fasting C-peptide, but insulin maintained stimulated C-peptide better than SU (one study, mean difference 7.7 ng/ml (95% CI 2.9 to 12.5) and insulin with rosiglitazone was superior to insulin alone (one study) at maintaining stimulated C-peptide. Rosiglitazone 182-195 insulin Homo sapiens 169-176 17486315-8 2007 Rosiglitazone treatment significantly increased insulin clearance (molar ratio of the C-peptide to insulin AUCs: 12.80 +/- 1.34 vs 11.38 +/- .33, p < 0.05) and the insulin sensitivity index (12.0 +/- 1.5 vs 8.5 +/- 1.1 micromol m(-2) min(-1) pmol(-1)l, p < 0.01). Rosiglitazone 0-13 insulin Homo sapiens 48-55 17486315-8 2007 Rosiglitazone treatment significantly increased insulin clearance (molar ratio of the C-peptide to insulin AUCs: 12.80 +/- 1.34 vs 11.38 +/- .33, p < 0.05) and the insulin sensitivity index (12.0 +/- 1.5 vs 8.5 +/- 1.1 micromol m(-2) min(-1) pmol(-1)l, p < 0.01). Rosiglitazone 0-13 insulin Homo sapiens 99-106 17486315-8 2007 Rosiglitazone treatment significantly increased insulin clearance (molar ratio of the C-peptide to insulin AUCs: 12.80 +/- 1.34 vs 11.38 +/- .33, p < 0.05) and the insulin sensitivity index (12.0 +/- 1.5 vs 8.5 +/- 1.1 micromol m(-2) min(-1) pmol(-1)l, p < 0.01). Rosiglitazone 0-13 insulin Homo sapiens 99-106 17486315-9 2007 CONCLUSIONS/INTERPRETATION: The present results show that a single dose of rosiglitazone rapidly increases insulin clearance and insulin sensitivity index in healthy volunteers, with no direct effect on insulin secretion. Rosiglitazone 75-88 insulin Homo sapiens 107-114 17486315-9 2007 CONCLUSIONS/INTERPRETATION: The present results show that a single dose of rosiglitazone rapidly increases insulin clearance and insulin sensitivity index in healthy volunteers, with no direct effect on insulin secretion. Rosiglitazone 75-88 insulin Homo sapiens 129-136 17592102-7 2007 CONCLUSIONS: The addition of low-dose rosiglitazone to insulin therapy is an effective and well-tolerated treatment option for patients with type 2 diabetes mellitus who continue to have poor glycemic control despite administration of exogenous insulin as monotherapy. Rosiglitazone 38-51 insulin Homo sapiens 245-252 17592102-0 2007 Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes. Rosiglitazone 9-22 insulin Homo sapiens 40-47 17403121-1 2007 AIMS: To compare the efficacy and safety of either continuing or discontinuing rosiglitazone + metformin fixed-dose combination when starting insulin therapy in people with Type 2 diabetes inadequately controlled on oral therapy. Rosiglitazone 79-92 insulin Homo sapiens 142-149 17403121-3 2007 RESULTS: Insulin dose at week 24 was significantly lower with rosiglitazone + metformin (33.5 +/- 1.5 U/day, mean +/- se) compared with placebo [59.0 +/- 3.0 U/day; model-adjusted difference -26.6 (95% CI -37.7, -15,5) U/day, P < 0.001]. Rosiglitazone 62-75 insulin Homo sapiens 9-16 17403436-11 2007 In addition, we suggest that rosiglitazone may be more beneficial than metformin therapy on raised insulin and androgen levels in an obese PCOS population. Rosiglitazone 29-42 insulin Homo sapiens 99-106 17403121-8 2007 CONCLUSIONS: Addition of insulin to rosiglitazone + metformin enabled more people to reach glycaemic targets with less insulin, and was generally well tolerated. Rosiglitazone 36-49 insulin Homo sapiens 119-126 17339547-3 2007 We therefore hypothesized that insulin-resistant apoE-deficient (apoE-/-) mice would develop PAH that could be reversed by a peroxisome proliferator-activated receptor-gamma agonist (eg, rosiglitazone). Rosiglitazone 187-200 insulin Homo sapiens 31-38 17090751-11 2007 Rosiglitazone (RSG) significantly reduced both fasting serum insulin levels (reduced by 51%, P=0.0395) and serum LPS (reduced by 35%, P=0.0139) in a subgroup of previously untreated T2DM patients. Rosiglitazone 0-13 insulin Homo sapiens 61-68 17303006-8 2007 CONCLUSION: YY20, a potential insulin-sensitizing agent like rosiglitazone, could enhance glucose consumption in HepG2 cells in a concentration- and insulindependent manner. Rosiglitazone 61-74 insulin Homo sapiens 30-37 17090751-11 2007 Rosiglitazone (RSG) significantly reduced both fasting serum insulin levels (reduced by 51%, P=0.0395) and serum LPS (reduced by 35%, P=0.0139) in a subgroup of previously untreated T2DM patients. Rosiglitazone 15-18 insulin Homo sapiens 61-68 17331860-9 2007 Metformin and rosiglitazone significantly decreased levels of triglyceride (TG), low-density lipoprotein (LDL), total cholesterol (total-C), HbA1c, insulin, and homeostasis model assessment (HOMA). Rosiglitazone 14-27 insulin Homo sapiens 148-155 17106061-8 2007 Pioglitazone and rosiglitazone similarly improved FPG, mean plasma glucose during OGTT, Hb A1c, and insulin-mediated total body glucose disposal (Rd) and decreased mean plasma FFA during OGTT (all P<0.01, ANOVA). Rosiglitazone 17-30 insulin Homo sapiens 100-107 18220657-1 2007 The thiazolidinediones (TZDs) rosiglitazone (ROS) and pioglitazone (PIO) are insulin-sensitising agents widely used to treat patients with type 2 diabetes mellitus (T2DM). Rosiglitazone 30-43 insulin Homo sapiens 77-84 17224000-8 2007 RESULTS: Improvements in fasting insulin level, QUICKI and HOMA-beta were noted in the rosiglitazone-treated group. Rosiglitazone 87-100 insulin Homo sapiens 33-40 19888409-0 2007 Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. Rosiglitazone 25-38 insulin Homo sapiens 70-77 19888409-6 2007 RESULTS: Both drugs improved ovulation, and an increase in insulin sensitivity was observed, especially in the rosiglitazone arm. Rosiglitazone 111-124 insulin Homo sapiens 59-66 18220657-1 2007 The thiazolidinediones (TZDs) rosiglitazone (ROS) and pioglitazone (PIO) are insulin-sensitising agents widely used to treat patients with type 2 diabetes mellitus (T2DM). Rosiglitazone 45-48 insulin Homo sapiens 77-84 17148569-6 2007 CONCLUSIONS: These results suggest that the insulin-sensitizing action of rosiglitazone involves remodeling of human adipose tissue to reduce inflammation and promote lipid storage. Rosiglitazone 74-87 insulin Homo sapiens 44-51 17287417-4 2007 The aim of this study was to examine the effects of 4 months of treatment with the insulin sensitizer rosiglitazone on plasma adiponectin, resistin and ghrelin levels in overweight women with PCOS. Rosiglitazone 102-115 insulin Homo sapiens 83-90 17287417-12 2007 CONCLUSIONS: Rosiglitazone had beneficial effects on serum levels of adiponectin and resistin, suggesting that these adipocytokines may contribute to the improvement in insulin sensitivity observed during the treatment. Rosiglitazone 13-26 insulin Homo sapiens 169-176 17612907-0 2007 Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance. Rosiglitazone 0-13 insulin Homo sapiens 126-133 17612907-10 2007 CONCLUSIONS: RSG treatment for 1 year was associated with a small but significant decrease in diastolic 24-h ambulatory diastolic BP, and both systolic and diastolic office BPs in non-diabetic people with insulin resistance. Rosiglitazone 13-16 insulin Homo sapiens 205-212 17040956-9 2007 Furthermore, rosiglitazone-mediated decreases in lipocalin-2 concentrations correlated significantly with increases in insulin sensitivity (r = 0.527; P = 0.002) and decreases in hs-CRP concentrations (r = 0.509; P = 0.003). Rosiglitazone 13-26 insulin Homo sapiens 119-126 17174222-6 2007 Rosiglitazone therapy reduced plasma insulin, proinsulin, split proinsulin and free fatty acid levels compared with glibenclamide. Rosiglitazone 0-13 insulin Homo sapiens 37-44 17189867-0 2007 Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled type 2 diabetes mellitus patients treated with insulin alone. Rosiglitazone 0-13 insulin Homo sapiens 131-138 17189867-13 2007 CONCLUSION: Rosiglitazone+insulin combination is safe and effective in inadequately controlled insulin-treated T2DM patients. Rosiglitazone 12-25 insulin Homo sapiens 95-102 17200362-8 2007 Treatment with rosiglitazone resulted in increased serum adiponectin (P < 0.001), decreased insulin levels (P = 0.005), and increased insulin sensitivity (P = 0.004). Rosiglitazone 15-28 insulin Homo sapiens 95-102 17200362-8 2007 Treatment with rosiglitazone resulted in increased serum adiponectin (P < 0.001), decreased insulin levels (P = 0.005), and increased insulin sensitivity (P = 0.004). Rosiglitazone 15-28 insulin Homo sapiens 137-144 18062722-1 2007 Rosiglitazone (Avandia) is an antihyperglycaemic agent of the thiazolidinedione class that improves glycaemic control (as indicated by glycosylated haemoglobin [HbA1c] and fasting plasma glucose [FPG] levels) primarily by increasing hepatic and peripheral insulin sensitivity, and in addition may help to preserve pancreatic beta-cell function. Rosiglitazone 0-13 insulin Homo sapiens 256-263 17161222-12 2007 After rosiglitazone therapy, the mean serum insulin and C-peptide levels at fasting remained unchanged. Rosiglitazone 6-19 insulin Homo sapiens 44-51 17161222-19 2007 We conclude that rosiglitazone therapy improved overall glucose tolerance and enhanced insulin sensitivity in patients with IGT and type 2 DM. Rosiglitazone 17-30 insulin Homo sapiens 87-94 17174222-11 2007 However, rosiglitazone reduced insulin resistance and proinsulin levels whereas glibenclamide use was associated with an increase in fasting insulin and proinsulin. Rosiglitazone 9-22 insulin Homo sapiens 31-38 17174222-6 2007 Rosiglitazone therapy reduced plasma insulin, proinsulin, split proinsulin and free fatty acid levels compared with glibenclamide. Rosiglitazone 0-13 insulin Homo sapiens 46-56 17174222-6 2007 Rosiglitazone therapy reduced plasma insulin, proinsulin, split proinsulin and free fatty acid levels compared with glibenclamide. Rosiglitazone 0-13 insulin Homo sapiens 64-74 17174222-7 2007 Rosiglitazone improved insulin resistance while a worsening was seen with glibenclamide. Rosiglitazone 0-13 insulin Homo sapiens 23-30 17892035-9 2007 We noticed decrease in insulin area under the curve after 3 and 6 months of rosiglitazon (respectively p = 0.029 and 0.03). Rosiglitazone 76-88 insulin Homo sapiens 23-30 17145645-5 2006 The insulin-sensitizing agents available commercially include metformin, rosiglitazone and pioglitazone. Rosiglitazone 73-86 insulin Homo sapiens 4-11 17580731-3 2007 While glimepiride stimulates beta-cell secretion and leads to reduction of blood glucose values, rosiglitazone activates PPARgamma and improves insulin resistance, at the vascular and metabolically active cells. Rosiglitazone 97-110 insulin Homo sapiens 144-151 17294577-3 2006 On the other hand, rosiglitazone, a thiazolidinedione, can reduce insulin resistance and might preserve insulin secretion. Rosiglitazone 19-32 insulin Homo sapiens 66-73 17294577-3 2006 On the other hand, rosiglitazone, a thiazolidinedione, can reduce insulin resistance and might preserve insulin secretion. Rosiglitazone 19-32 insulin Homo sapiens 104-111 17345784-1 2006 The aim of our study was to investigate the metabolic effect of telmisartan and irbesartan in subjects treated with rosiglitazone, a well-known insulin-sensitizing drug, in order to clarify the direct metabolic effects of the two former drugs. Rosiglitazone 116-129 insulin Homo sapiens 144-151 16804037-0 2006 Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. Rosiglitazone 9-22 insulin Homo sapiens 131-138 16896939-0 2006 Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: role of adipose tissue and skeletal muscle in response to rosiglitazone. Rosiglitazone 137-150 insulin Homo sapiens 0-7 17039655-3 2006 Metformin and rosiglitazone are 2 pharmacologic agents useful in conditions characterized by insulin resistance. Rosiglitazone 14-27 insulin Homo sapiens 93-100 17039655-6 2006 RESULTS: Only the rosiglitazone group showed a significant reduction in insulin levels. Rosiglitazone 18-31 insulin Homo sapiens 72-79 16997664-1 2006 BACKGROUND: Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. Rosiglitazone 12-25 insulin Homo sapiens 62-69 16997664-1 2006 BACKGROUND: Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. Rosiglitazone 12-25 insulin Homo sapiens 100-107 16822823-1 2006 CONTEXT: Activation of peroxisome proliferator-activated receptors (PPARs)-gamma by thiazolidinediones (pioglitazone, rosiglitazone) and dual-acting PPARalpha/gamma agonists (pargluva, ragaglitazar) is a widely used pharmacological principle to treat insulin resistance and type 2 diabetes. Rosiglitazone 118-131 insulin Homo sapiens 251-258 16804037-2 2006 HYPOTHESIS: Because inflammatory mediators interfere with insulin signal transduction, we have now hypothesized that rosiglitazone exerts an initial antiinflammatory effect independently of its metabolic actions including the suppression of the plasma concentration of free fatty acids (FFAs), insulin, and glucose after which insulin sensitization occurs. Rosiglitazone 117-130 insulin Homo sapiens 58-65 16804037-2 2006 HYPOTHESIS: Because inflammatory mediators interfere with insulin signal transduction, we have now hypothesized that rosiglitazone exerts an initial antiinflammatory effect independently of its metabolic actions including the suppression of the plasma concentration of free fatty acids (FFAs), insulin, and glucose after which insulin sensitization occurs. Rosiglitazone 117-130 insulin Homo sapiens 294-301 16804037-2 2006 HYPOTHESIS: Because inflammatory mediators interfere with insulin signal transduction, we have now hypothesized that rosiglitazone exerts an initial antiinflammatory effect independently of its metabolic actions including the suppression of the plasma concentration of free fatty acids (FFAs), insulin, and glucose after which insulin sensitization occurs. Rosiglitazone 117-130 insulin Homo sapiens 294-301 16804037-11 2006 CONCLUSIONS: A low dose of rosiglitazone exerts an early and potent antiinflammatory effect with an increase in adiponectin and a fall in resistin concentrations without causing any metabolic changes (fall in plasma glucose, FFAs, and insulin concentrations) over a 6-wk period. Rosiglitazone 27-40 insulin Homo sapiens 235-242 16682454-1 2006 Adipogenesis is an important process for the improvement of insulin resistance by peroxisome proliferator-activated receptor (PPAR) gamma agonists, such as rosiglitazone and pioglitazone. Rosiglitazone 156-169 insulin Homo sapiens 60-67 16765099-7 2006 In vivo, although rosiglitazone significantly lowered both glucose (33%, p<0.01) and insulin (61%, p<0.01) levels and increased expression of adiponectin (74%, p<0.001), sartan treatment had no effect. Rosiglitazone 18-31 insulin Homo sapiens 88-95 16501039-5 2006 Glucose tolerance [expressed as AUC(glucose) during the OGTT] improved (P = 0.002) and peripheral insulin response (expressed as AUC(insulin)) decreased (P = 0.004) in the rosiglitazone group (ROSI group). Rosiglitazone 172-185 insulin Homo sapiens 98-105 16682454-7 2006 Furthermore, the long-term treatment of mature adipocytes with rosiglitazone and pioglitazone reduced the expression of phosphodiesterase 3B, the down-regulation of which has an important role in the development of insulin resistance; however, FK614 had no such effect in mature adipocytes. Rosiglitazone 63-76 insulin Homo sapiens 215-222 16501039-5 2006 Glucose tolerance [expressed as AUC(glucose) during the OGTT] improved (P = 0.002) and peripheral insulin response (expressed as AUC(insulin)) decreased (P = 0.004) in the rosiglitazone group (ROSI group). Rosiglitazone 172-185 insulin Homo sapiens 133-140 16501039-7 2006 CONCLUSION: Rosiglitazone, by improving menstrual cyclicity, hyperandrogenism, insulin resistance and hyperinsulinaemia, represents an alternative treatment for overweight anovulatory women with PCOS and no pregnancy desire. Rosiglitazone 12-25 insulin Homo sapiens 79-86 16932451-0 2006 Do patients with type 2 diabetes on peritoneal dialysis need less insulin if they are given rosiglitazone? Rosiglitazone 92-105 insulin Homo sapiens 66-73 16751941-1 2006 OBJECTIVE: To evaluate the effects of rosiglitazone (ROSI), an insulin-sensitizer, on endothelial function and endothelial activation markers in a group of non-diabetic subjects with metabolic syndrome. Rosiglitazone 38-51 insulin Homo sapiens 63-70 16751941-10 2006 CONCLUSION: Rosiglitazone treatment reduced insulin resistance, fibrinogen, and CRP levels and improved endothelial function in non-diabetic subjects with metabolic syndrome. Rosiglitazone 12-25 insulin Homo sapiens 44-51 16367882-6 2006 RSG + SU significantly decreased HbA(1c), FPG, insulin resistance, plasma free fatty acids and medical care utilization and improved treatment satisfaction compared with uptitrated SU. Rosiglitazone 0-3 insulin Homo sapiens 47-54 16384852-8 2006 Rosiglitazone treatment for 8 wk significantly increased insulin sensitivity and muscle UCP3 content (from 53.2 +/- 29.9 to 66.3 +/- 30.9 arbitrary units; P < 0.05). Rosiglitazone 0-13 insulin Homo sapiens 57-64 16546473-0 2006 Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein. Rosiglitazone 0-13 insulin Homo sapiens 23-30 16546473-10 2006 We conclude that ROS effectively enhanced insulin sensitivity and beta-cell function to improve adiponectin and CRP levels in nonobese patients with IGT. Rosiglitazone 17-20 insulin Homo sapiens 42-49 16352689-9 2006 During both clamp steps, RSG enhanced insulin-mediated glucose clearance (by 26% and 31%; P = 0.01 and P < 0.02, respectively). Rosiglitazone 25-28 insulin Homo sapiens 38-45 16352689-11 2006 CONCLUSION/INTERPRETATION: RSG increases peripheral tissue insulin sensitivity and decreases endogenous glucose release via an inhibition of gluconeogenesis. Rosiglitazone 27-30 insulin Homo sapiens 59-66 16367888-6 2006 Resistin 1 microm significantly reduced maximum insulin-stimulated 2-deoxyglucose uptake in L6 cells from 634 to 383% (relative to 100% for control, p < 0.001), and co-administration of rosiglitazone had no effect on resistin-induced insulin resistance. Rosiglitazone 189-202 insulin Homo sapiens 48-55 16360262-8 2006 Much better decrease in the level of testosterone and free androgen index was established in group treated with metformin, while the indices of insulin resistance were better influenced in the group treated with rosiglitazone. Rosiglitazone 212-225 insulin Homo sapiens 144-151 16360262-10 2006 In cases with PCOS metformin treatment influences better hyperandrogenemia, while rosiglitazone affects more pronouncedly insulin resistance and hyperinsulinemia. Rosiglitazone 82-95 insulin Homo sapiens 122-129 16505510-9 2006 CONCLUSIONS: Rosiglitazone improved insulin sensitivity but had no effect on NO-dependent vasodilatation in the forearm or vascular permeability in obese, insulin-resistant, nondiabetic subjects. Rosiglitazone 13-26 insulin Homo sapiens 36-43 16505510-11 2006 Nonetheless, rosiglitazone-induced improvement in insulin sensitivity appears to be correlated to edema formation. Rosiglitazone 13-26 insulin Homo sapiens 50-57 16444435-12 2006 Insulin sensitivity significantly improved after the addition of rosiglitazone treatment in diabetic patients (p < 0.01). Rosiglitazone 65-78 insulin Homo sapiens 0-7 16444435-13 2006 The short-term and low-dose treatment with rosiglitazone in type 2 diabetic patients has no effects on the fibrinolytic system, although it improves insulin sensitivity. Rosiglitazone 43-56 insulin Homo sapiens 149-156 16914073-3 2006 Two key classes of insulin-sensitizing agents--the biguanides (principally metformin) and thiazolidinediones (pioglitazone and rosiglitazone)--have distinct molecular mechanisms of action and differing effects on metabolic dysfunction. Rosiglitazone 127-140 insulin Homo sapiens 19-26 16155076-0 2006 Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Rosiglitazone 33-46 insulin Homo sapiens 73-80 16155076-9 2006 Both before and during treatment, ovulators on rosiglitazone had lower circulating insulin and free testosterone and higher SHBG than non-ovulators. Rosiglitazone 47-60 insulin Homo sapiens 83-90 16155076-11 2006 CONCLUSIONS: Rosiglitazone in insulin-resistant PCOS promoted ovulation and dose-dependently decreased IR and insulinaemia; ovulators had lower circulating insulin and testosterone. Rosiglitazone 13-26 insulin Homo sapiens 30-37 16155076-11 2006 CONCLUSIONS: Rosiglitazone in insulin-resistant PCOS promoted ovulation and dose-dependently decreased IR and insulinaemia; ovulators had lower circulating insulin and testosterone. Rosiglitazone 13-26 insulin Homo sapiens 110-117 16199428-0 2006 Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Rosiglitazone 0-13 insulin Homo sapiens 144-151 16199428-5 2006 Rosiglitazone reduced insulin, IR indices [homeostasis model assessment (HOMA) and quantitative sensitivity check index (QUICKI)] and the insulin area under the curve in response to an oral glucose tolerance test (OGTT), but had limited effect on lipids, androgens and hirsutism. Rosiglitazone 0-13 insulin Homo sapiens 22-29 16199428-9 2006 CONCLUSIONS: In obese PCOS women with high insulin not corrected by diet, the combination of rosiglitazone and EE/CPA may be used to achieve complementary beneficial effects on endocrine-metabolic anomalies and clinical symptoms. Rosiglitazone 93-106 insulin Homo sapiens 43-50 16369466-2 2006 The present investigation was a logical extension of a previous work, examining isometric exercise performance and recovery in people with diabetes and the impact of the insulin sensitizer rosiglitazone, a drug shown to improve endothelial function. Rosiglitazone 189-202 insulin Homo sapiens 170-177 16719233-3 2006 A novel oral hypoglycaemic agent, rosiglitazone, targeting insulin resistance, not yet registered in our country, has been available in majority of Europian countries. Rosiglitazone 34-47 insulin Homo sapiens 59-66 16719233-13 2006 Treatment with rosiglitazone lead to improved insulin sensitivity which may predict longer term preservation of B-cell function. Rosiglitazone 15-28 insulin Homo sapiens 46-53 16800162-5 2006 RESULTS: Rosiglitazone in combination with metformin produces better glycaemic control than conventional care of metformin in combination with either sulfonylureas or bedtime insulin in most patients, and extends the viability of combination therapy by between 6 and 13 years before requiring insulin. Rosiglitazone 9-22 insulin Homo sapiens 293-300 16324915-7 2006 Substantial and significant dose-dependent improvements were observed after addition of rosiglitazone for fasting glucose (group 0, -9 +/- 48 mg/dL; group 4, -38 +/- 47 mg/dL; group 8, -46 +/- 53 mg/dL), HbA1c (-0.1% +/- 0.7%, -1.1% +/- 1.2%, -1.3% +/- 1.2%), insulin (1.4 +/- 6.2, -1.2 +/- 5.3, -3.7 +/- 9.9 microU/mL), intact proinsulin (1.6 +/- 7.1, -2.0 +/- 4.6, -3.1 +/- 6.1 pmol/L), and high-sensitivity C-reactive protein (0.2 +/- 2.6, -1.7 +/- 3.5, -2.1 +/- 3.5 mg/L). Rosiglitazone 88-101 insulin Homo sapiens 260-267 16324915-9 2006 The number of insulin-resistant patients decreased in both rosiglitazone treatment groups, whereas no change was seen with glimepiride alone. Rosiglitazone 59-72 insulin Homo sapiens 14-21 16324915-10 2006 Next to the reported effects on glucose control, rosiglitazone provided an additional beneficial effect on insulin resistance, beta-cell function, and cardiovascular risk markers. Rosiglitazone 49-62 insulin Homo sapiens 107-114 16800161-7 2006 RESULTS: The combination therapy of rosiglitazone with metformin or sulfonylurea produces better glycaemic control than conventional care of metformin with sulfonylurea and insulin in most patients, extends the viability of oral therapy before requiring insulin, and typically leads to lifetime cost increases across all treatment types. Rosiglitazone 36-49 insulin Homo sapiens 173-180 16800161-7 2006 RESULTS: The combination therapy of rosiglitazone with metformin or sulfonylurea produces better glycaemic control than conventional care of metformin with sulfonylurea and insulin in most patients, extends the viability of oral therapy before requiring insulin, and typically leads to lifetime cost increases across all treatment types. Rosiglitazone 36-49 insulin Homo sapiens 254-261 16800162-1 2006 OBJECTIVE: To assess the lifetime diabetes health consequences and cost-effectiveness in Spain of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in overweight and obese patients failing to maintain glycaemic control with metformin monotherapy compared with conventional care of metformin in combination with either sulfonylureas or bedtime insulin. Rosiglitazone 98-111 insulin Homo sapiens 374-381 16189256-1 2005 CONTEXT: We have shown that rosiglitazone increases whole-body and adipose tissue insulin sensitivity in humans. Rosiglitazone 28-41 insulin Homo sapiens 82-89 16189256-7 2005 RESULTS: Metformin and rosiglitazone treatment improved glycemic control, but only rosiglitazone increased whole-body insulin sensitivity. Rosiglitazone 83-96 insulin Homo sapiens 118-125 16189256-12 2005 Rosiglitazone treatment enhances GU and flow but decreases glucose extraction, suggesting that perfusion may contribute to adipose tissue insulin sensitization by rosiglitazone. Rosiglitazone 0-13 insulin Homo sapiens 138-145 16189256-12 2005 Rosiglitazone treatment enhances GU and flow but decreases glucose extraction, suggesting that perfusion may contribute to adipose tissue insulin sensitization by rosiglitazone. Rosiglitazone 163-176 insulin Homo sapiens 138-145 16219007-2 2005 Thiazolidinediones such as rosiglitazone and pioglitazone enhance insulin-mediated glucose disposal, leading to reduced plasma insulin concentrations. Rosiglitazone 27-40 insulin Homo sapiens 66-73 16340782-2 2005 Because insulin resistance plays a significant role in the development of PTDM, we treated 40 consecutive patients with PTDM after liver and kidney transplantation with the insulin sensitizer rosiglitazone (ROSI). Rosiglitazone 192-205 insulin Homo sapiens 8-15 16340782-2 2005 Because insulin resistance plays a significant role in the development of PTDM, we treated 40 consecutive patients with PTDM after liver and kidney transplantation with the insulin sensitizer rosiglitazone (ROSI). Rosiglitazone 192-205 insulin Homo sapiens 173-180 16340782-2 2005 Because insulin resistance plays a significant role in the development of PTDM, we treated 40 consecutive patients with PTDM after liver and kidney transplantation with the insulin sensitizer rosiglitazone (ROSI). Rosiglitazone 207-211 insulin Homo sapiens 173-180 16340782-7 2005 After 3-4 months of insulin and ROSI therapy, insulin was able to be discontinued in 30/33 (91%) patients with PTDM. Rosiglitazone 32-36 insulin Homo sapiens 46-53 16483179-1 2005 AIM: The aim of this study was to assess the effects of metformin and rosiglitazone on insulin resistance and serum androgen levels in both obese and lean patients with polycystic ovary syndrome (PCOS). Rosiglitazone 70-83 insulin Homo sapiens 87-94 16483179-14 2005 CONCLUSIONS: Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well. Rosiglitazone 53-66 insulin Homo sapiens 77-84 16219007-2 2005 Thiazolidinediones such as rosiglitazone and pioglitazone enhance insulin-mediated glucose disposal, leading to reduced plasma insulin concentrations. Rosiglitazone 27-40 insulin Homo sapiens 127-134 16219011-2 2005 Metformin and thiazolidinediones (pioglitazone and rosiglitazone) counter insulin resistance by different cellular mechanisms and with complementary effects, making them suited for use in combination. Rosiglitazone 51-64 insulin Homo sapiens 74-81 16183427-0 2005 Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Rosiglitazone 0-13 insulin Homo sapiens 22-29 16131582-9 2005 Both rosiglitazone and pioglitazone abolished insulin-dependent stimulation of estradiol production in the presence of FSH. Rosiglitazone 5-18 insulin Homo sapiens 46-53 16131582-10 2005 Rosiglitazone and pioglitazone inhibited testosterone production by 10% (P < 0.012) and 15% (P < 0.023), respectively, and abolished insulin-induced stimulation of testosterone production. Rosiglitazone 0-13 insulin Homo sapiens 139-146 16131582-12 2005 Pioglitazone and rosiglitazone enhanced insulin-induced inhibition of IGFBP-1 production by 13% and 20%, respectively (P < 0.001). Rosiglitazone 17-30 insulin Homo sapiens 40-47 16183427-4 2005 Rosiglitazone (RSG), a thiazolidinedione, can improve insulin resistance, and its excretion does not rely on renal function. Rosiglitazone 0-13 insulin Homo sapiens 54-61 16183427-4 2005 Rosiglitazone (RSG), a thiazolidinedione, can improve insulin resistance, and its excretion does not rely on renal function. Rosiglitazone 15-18 insulin Homo sapiens 54-61 16183427-10 2005 Insulin requirement was decreased significantly in the RSG group (27.88 +/- 17.6 to 22.4 +/- 15.21 U/d; P < 0.001). Rosiglitazone 55-58 insulin Homo sapiens 0-7 16183427-11 2005 There was a significantly greater decrease in insulin dosage in the RSG than control group (-21.5% versus +0.5%; P = 0.03), whereas glycemic control was similar between groups. Rosiglitazone 68-71 insulin Homo sapiens 46-53 16183427-15 2005 Multivariate regression analysis (using decrease in HbA1c and lipid levels, change in insulin dosage, and treatment with RSG, with lipid-lowering agents) showed that only treatment with RSG was an independent predictor for posttreatment CRP level (P = 0.016). Rosiglitazone 186-189 insulin Homo sapiens 86-93 16183427-16 2005 CONCLUSION: RSG in combination with insulin is well tolerated and beneficial in the treatment of patients with type 2 diabetes on peritoneal dialysis therapy by improving insulin sensitivity and decreasing inflammatory response. Rosiglitazone 12-15 insulin Homo sapiens 171-178 16231594-7 2005 Two classes of drugs have been shown to correct insulin resistance: biguanides (e.g., metformin) and thiazolidinediones (e.g., rosiglitazone and pioglitazone). Rosiglitazone 127-140 insulin Homo sapiens 48-55 16126119-2 2005 As diabetes and hypertension share common ground in insulin resistance, the aim of this study was to evaluate if Rosiglitazone (RSG) may exert antihypertensive properties. Rosiglitazone 113-126 insulin Homo sapiens 52-59 16126119-13 2005 These findings indicate firstly that RSG is able to induce a reduction of BP and secondly the amelioration of insulin sensitivity is associated with the reduction of BP. Rosiglitazone 37-40 insulin Homo sapiens 110-117 16259488-9 2005 Rosiglitazone monotherapy improved insulin resistance but not overall beta-cell secretion. Rosiglitazone 0-13 insulin Homo sapiens 35-42 16200335-2 2005 Treatment with insulin sensitizers (metformin, rosiglitazone) can ameliorate insulin resistance. Rosiglitazone 47-60 insulin Homo sapiens 15-22 16200335-2 2005 Treatment with insulin sensitizers (metformin, rosiglitazone) can ameliorate insulin resistance. Rosiglitazone 47-60 insulin Homo sapiens 77-84 16200335-11 2005 Furthermore, after 48 weeks of treatment the fasting insulin concentration in the rosiglitazone group declined by 49% and in the metformin group by 28%. Rosiglitazone 82-95 insulin Homo sapiens 53-60 16200335-12 2005 This improvement in insulin secretion could be clearly demonstrated when the sums of insulin concentrations after oral glucose tolerance test were compared: 548-/+13 to 345-/+11.8 mIU/l in the rosiglitazone group (37% decrease, p<0.01) and from 552-/+15 to 420-/+12 mIU/l in the metformin group (24% decrease, p<0.01). Rosiglitazone 193-206 insulin Homo sapiens 20-27 16025252-8 2005 The same criterion for failure of triple oral drug therapy in the rosiglitazone-treated group is used for starting insulin in this group. Rosiglitazone 66-79 insulin Homo sapiens 115-122 16259488-17 2005 SUMMARY: Rosiglitazone improved glucose homeostasis and insulin resistance in high-risk African Americans. Rosiglitazone 9-22 insulin Homo sapiens 56-63 16117910-10 2005 The thiazolidinediones (pio- and rosiglitazone), a novel class of insulin-sensitising agents, also seem to ameliorate the metabolic disturbances and clinical symptoms characterizing PCOS, but more randomised, controlled trials are needed before clinical guidelines can be determined. Rosiglitazone 33-46 insulin Homo sapiens 66-73 15864539-11 2005 These data show that chronic treatment of human myotubes with insulin, metformin or rosiglitazone has a direct positive effect on insulin action and mRNA expression. Rosiglitazone 84-97 insulin Homo sapiens 130-137 15983223-3 2005 We therefore investigated whether rosiglitazone, an insulin-sensitizing drug that is known to improve endothelial dysfunction, was able to improve intrarenal endothelial dysfunction and microalbuminuria. Rosiglitazone 34-47 insulin Homo sapiens 52-59 15994753-10 2005 Insulin resistance indices were significantly improved after rosiglitazone treatment (P < 0.05). Rosiglitazone 61-74 insulin Homo sapiens 0-7 15994753-17 2005 CONCLUSIONS: We conclude that rosiglitazone treatment improves insulin sensitivity in women with PCOS. Rosiglitazone 30-43 insulin Homo sapiens 63-70 15864539-0 2005 Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1. Rosiglitazone 84-97 insulin Homo sapiens 9-16 15955124-3 2005 We examined whether the insulin-sensitizing agents, metformin and rosiglitazone, improve intestinal lipoprotein metabolism in obese insulin-resistant individuals. Rosiglitazone 66-79 insulin Homo sapiens 24-31 15955124-6 2005 RESULTS: Metformin and rosiglitazone both significantly improved insulin sensitivity, but this was not paralleled by improvement in dyslipidaemia. Rosiglitazone 23-36 insulin Homo sapiens 65-72 15955124-8 2005 CONCLUSION: In obese insulin-resistant subjects metformin and rosiglitazone both improve insulin sensitivity, as measured by HOMA, without improvement in lipid metabolism. Rosiglitazone 62-75 insulin Homo sapiens 21-28 15864539-5 2005 RESULTS: Insulin-stimulated glycogen synthesis was significantly increased in cultured human myotubes treated with insulin, rosiglitazone or metformin for 8 days, compared with non-treated cells. Rosiglitazone 124-137 insulin Homo sapiens 9-16 15842531-0 2005 Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? Rosiglitazone 0-13 insulin Homo sapiens 23-30 16006724-8 2005 This study demonstrated that rosiglitazone improves the ovulatory dysfunction, hirsutism, hyperandrogenemia, and insulin resistance of PCOS in a dose-related fashion, with minimal adverse effects. Rosiglitazone 29-42 insulin Homo sapiens 113-120 15855334-0 2005 Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Rosiglitazone 25-38 insulin Homo sapiens 52-59 15855334-1 2005 The effect of metformin or rosiglitazone monotherapy versus placebo on insulin signaling and gene expression in skeletal muscle of patients with newly diagnosed type 2 diabetes was determined. Rosiglitazone 27-40 insulin Homo sapiens 71-78 15855334-3 2005 Insulin-mediated whole-body and leg muscle glucose uptake was enhanced 36 and 32%, respectively, after rosiglitazone (P < 0.01) but not after metformin or placebo treatment. Rosiglitazone 103-116 insulin Homo sapiens 0-7 16006724-1 2005 We hypothesized that the administration of rosiglitazone, an insulin-sensitizing agent of the thiazolidinedione class, would improve the ovulatory dysfunction, hirsutism, hyperandrogenemia, and hyperinsulinemia of polycystic ovary syndrome (PCOS) patients. Rosiglitazone 43-56 insulin Homo sapiens 61-68 15855323-0 2005 Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma. Rosiglitazone 0-13 insulin Homo sapiens 87-94 15855323-11 2005 An increased SCD activity index may reflect increased lipogenesis and might contribute to insulin sensitization by rosiglitazone. Rosiglitazone 115-128 insulin Homo sapiens 90-97 15855334-8 2005 In conclusion, the insulin-sensitizing effects of rosiglitazone are independent of enhanced signaling of IRS-1/PI 3-kinase/Akt/AS160 in patients with newly diagnosed type 2 diabetes. Rosiglitazone 50-63 insulin Homo sapiens 19-26 15899724-9 2005 Decreases in fasting plasma insulin and postprandial plasma insulin were observed at 12 months (p<0.05 and p<0.01, respectively) compared with baseline values in the rosiglitazone group. Rosiglitazone 172-185 insulin Homo sapiens 28-35 15938589-6 2005 Patients receiving rosiglitazone experienced more rapid improvement in glycaemic control than those on glimepiride, and showed a significant improvement in insulin resistance-related parameters. Rosiglitazone 19-32 insulin Homo sapiens 156-163 15938589-8 2005 Rosiglitazone plus metformin significantly improved long-term control of insulin resistance-related parameters compared with glimepiride plus metformin, although glimepiride treatment was associated with a slight improvement in cholesterolaemia, not observed in the rosiglitazone-treated patients, and with significant improvements in non-traditional risk factors for cardiovascular disease, such as basal homocysteinaemia and plasma Lp(a) levels. Rosiglitazone 0-13 insulin Homo sapiens 73-80 15877288-1 2005 Rosiglitazone, an agonist of peroxisome proliferator-activated receptor-gamma (PPAR gamma ), is an insulin-sensitizing antidiabetic agent and inhibits restenosis in animal blood vessels. Rosiglitazone 0-13 insulin Homo sapiens 99-106 15877288-4 2005 After 6 months of rosiglitazone treatment, the plasma levels of fasting glucose and insulin and those of hemoglobin A1C and homeostasis model assessment of insulin resistance were significantly decreased in the rosiglitazone group as compared with baseline levels and those in the control group. Rosiglitazone 18-31 insulin Homo sapiens 84-91 15877288-4 2005 After 6 months of rosiglitazone treatment, the plasma levels of fasting glucose and insulin and those of hemoglobin A1C and homeostasis model assessment of insulin resistance were significantly decreased in the rosiglitazone group as compared with baseline levels and those in the control group. Rosiglitazone 18-31 insulin Homo sapiens 156-163 15877288-4 2005 After 6 months of rosiglitazone treatment, the plasma levels of fasting glucose and insulin and those of hemoglobin A1C and homeostasis model assessment of insulin resistance were significantly decreased in the rosiglitazone group as compared with baseline levels and those in the control group. Rosiglitazone 211-224 insulin Homo sapiens 84-91 15877288-4 2005 After 6 months of rosiglitazone treatment, the plasma levels of fasting glucose and insulin and those of hemoglobin A1C and homeostasis model assessment of insulin resistance were significantly decreased in the rosiglitazone group as compared with baseline levels and those in the control group. Rosiglitazone 211-224 insulin Homo sapiens 156-163 15899724-9 2005 Decreases in fasting plasma insulin and postprandial plasma insulin were observed at 12 months (p<0.05 and p<0.01, respectively) compared with baseline values in the rosiglitazone group. Rosiglitazone 172-185 insulin Homo sapiens 60-67 15899724-12 2005 CONCLUSIONS: The rosiglitazone-metformin combination significantly improved the long-term control of all insulin resistance-related parameters compared with the glimepiride-metformin combination. Rosiglitazone 17-30 insulin Homo sapiens 105-112 15844237-6 2005 For prevention and/or treatment, exercise and optimal diet are useful, and metformin and rosiglitazone have been shown to improve insulin resistance. Rosiglitazone 89-102 insulin Homo sapiens 130-137 15837949-0 2005 Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Rosiglitazone 109-122 insulin Homo sapiens 0-7 15837949-6 2005 We therefore examined the effect of rosiglitazone (RSG) on the insulin-mediated upregulation of the RAS. Rosiglitazone 36-49 insulin Homo sapiens 63-70 15837949-6 2005 We therefore examined the effect of rosiglitazone (RSG) on the insulin-mediated upregulation of the RAS. Rosiglitazone 51-54 insulin Homo sapiens 63-70 15837949-11 2005 Insulin increased TNF-alpha secretion in a concentration-dependent manner (P<0.01), whereas RSG (10 nmol/L) significantly reduced the insulin-mediated rise in TNF-alpha (P<0.001), as well as angiotensin and angiotensin II. Rosiglitazone 95-98 insulin Homo sapiens 137-144 15787606-7 2005 Treatment with rosiglitazone for 24 and 48 h increased insulin signalling and decreased IRS1 Ser-307 phosphorylation concomitantly. Rosiglitazone 15-28 insulin Homo sapiens 55-62 15773972-1 2005 The purpose of this study was to assess the safety and efficacy of the insulin sensitizer rosiglitazone in patients with new-onset diabetes mellitus (NODM) after renal transplantation. Rosiglitazone 90-103 insulin Homo sapiens 71-78 16305071-0 2005 Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Rosiglitazone 10-23 insulin Homo sapiens 86-93 15386806-11 2005 Furthermore, PCP (P = 0.004) and DeltaCP(P = 0.015) differences between 12th month and baseline were higher in insulin + RSG group than those in the insulin group. Rosiglitazone 121-124 insulin Homo sapiens 111-118 15736108-13 2005 Considering the potential role of resistin in insulin resistance, decrease in resistin levels may contribute to improving insulin action with rosiglitazone treatment. Rosiglitazone 142-155 insulin Homo sapiens 122-129 15700135-7 2005 Autotaxin expression was up-regulated by treatment with TNFalpha (insulin resistance-promoting cytokine), and down-regulated by rosiglitazone treatment (insulin-sensitising compound) in 3T3F442A adipocytes. Rosiglitazone 128-141 insulin Homo sapiens 153-160 16305071-5 2005 Significant relationships were not discerned between enhanced insulin sensitivity and related variables and decreases in inflammatory/vascular markers, suggesting that RSG-induced changes in the latter variables in insulin-resistant individuals might be at least partly independent of the effects of the drug on insulin action. Rosiglitazone 168-171 insulin Homo sapiens 215-222 16305071-5 2005 Significant relationships were not discerned between enhanced insulin sensitivity and related variables and decreases in inflammatory/vascular markers, suggesting that RSG-induced changes in the latter variables in insulin-resistant individuals might be at least partly independent of the effects of the drug on insulin action. Rosiglitazone 168-171 insulin Homo sapiens 215-222 15615809-0 2005 Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Rosiglitazone 26-39 insulin Homo sapiens 68-75 15615809-5 2005 The main objectives of the present study were to investigate the effect of 4 weeks" treatment with the PPAR-gamma agonist rosiglitazone on insulin sensitivity, plasma glucose and endothelial function in renal transplant recipients with glucose intolerance. Rosiglitazone 122-135 insulin Homo sapiens 139-146 15615809-12 2005 CONCLUSIONS: Four weeks" treatment with rosiglitazone was associated with increased insulin sensitivity, lowered fasting and 2 h plasma glucose and improved endothelial function in renal transplant recipients with glucose intolerance. Rosiglitazone 40-53 insulin Homo sapiens 84-91 15704569-2 2005 The glitazones (pioglitazone, rosiglitazone) impact directly and selectively on the key problem of insulin resistance. Rosiglitazone 30-43 insulin Homo sapiens 99-106 15654920-11 2005 Rosiglitazone ameliorates insulin resistance provoked by TNF-alpha, completely restoring insulin-stimulated glucose uptake in parallel to the insulin signalling cascade. Rosiglitazone 0-13 insulin Homo sapiens 26-33 15654920-11 2005 Rosiglitazone ameliorates insulin resistance provoked by TNF-alpha, completely restoring insulin-stimulated glucose uptake in parallel to the insulin signalling cascade. Rosiglitazone 0-13 insulin Homo sapiens 89-96 15654920-11 2005 Rosiglitazone ameliorates insulin resistance provoked by TNF-alpha, completely restoring insulin-stimulated glucose uptake in parallel to the insulin signalling cascade. Rosiglitazone 0-13 insulin Homo sapiens 89-96 15654920-12 2005 Accordingly, foetal brown adipocytes represent a model for investigating insulin action, as well as for the mechanism by which rosiglitazone increase insulin sensitivity under situations that mimic insulin resistance. Rosiglitazone 127-140 insulin Homo sapiens 150-157 15654920-12 2005 Accordingly, foetal brown adipocytes represent a model for investigating insulin action, as well as for the mechanism by which rosiglitazone increase insulin sensitivity under situations that mimic insulin resistance. Rosiglitazone 127-140 insulin Homo sapiens 150-157 15638875-0 2005 Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance. Rosiglitazone 0-13 insulin Homo sapiens 23-30 15751771-7 2005 Relative to placebo, at week 48, rosiglitazone decreased systolic blood pressure (8 mmHg, P=0.03), insulin (3 microIU/ml, P=0.02), insulin resistance (P=0.03) and leptin (0.6 ng/ml, P=0.02), whilst adiponectin was increased (3.3 microg/lml, P<0.0001). Rosiglitazone 33-46 insulin Homo sapiens 99-106 15751771-7 2005 Relative to placebo, at week 48, rosiglitazone decreased systolic blood pressure (8 mmHg, P=0.03), insulin (3 microIU/ml, P=0.02), insulin resistance (P=0.03) and leptin (0.6 ng/ml, P=0.02), whilst adiponectin was increased (3.3 microg/lml, P<0.0001). Rosiglitazone 33-46 insulin Homo sapiens 131-138 15638875-1 2005 OBJECTIVE: This study was designed to evaluate the effects of rosiglitazone (ROS) on insulin sensitivity, beta-cell function, and glycaemic response to glucose challenge and meal in subjects with impaired glucose tolerance (IGT). Rosiglitazone 62-75 insulin Homo sapiens 85-92 15638875-1 2005 OBJECTIVE: This study was designed to evaluate the effects of rosiglitazone (ROS) on insulin sensitivity, beta-cell function, and glycaemic response to glucose challenge and meal in subjects with impaired glucose tolerance (IGT). Rosiglitazone 77-80 insulin Homo sapiens 85-92 15638875-6 2005 The glucose, insulin, and c-peptide areas under curve (AUC) in response to OGTT and the glucose and insulin AUC during meal were significantly ameliorated in the ROS group. Rosiglitazone 162-165 insulin Homo sapiens 13-20 15638875-6 2005 The glucose, insulin, and c-peptide areas under curve (AUC) in response to OGTT and the glucose and insulin AUC during meal were significantly ameliorated in the ROS group. Rosiglitazone 162-165 insulin Homo sapiens 100-107 15638875-8 2005 CONCLUSION: Rosiglitazone treatment significantly improved insulin resistance and reduced postchallenge glucose and insulin concentrations in patients with impaired glucose tolerance without remarkable effects on beta-cell secretory function. Rosiglitazone 12-25 insulin Homo sapiens 59-66 15620433-11 2005 Even in Korean type 2 diabetic patients of long duration but with relatively preserved beta-cell function, rosiglitazone improved glycemic control, insulin sensitivity, and beta-cell function. Rosiglitazone 107-120 insulin Homo sapiens 148-155 15620433-12 2005 In this ethnic group, female gender, central obesity, and especially severe insulin resistance were identified as predictive clinical parameters of rosiglitazone-responders. Rosiglitazone 148-161 insulin Homo sapiens 76-83 15617852-11 2005 PPAR-gamma influences the gene expression involved in carbohydrate metabolism, and pioglitazone and rosiglitazone, ligands for PPAR-gamma, improve insulin resistance in diabetic patients. Rosiglitazone 100-113 insulin Homo sapiens 147-154 15483106-0 2005 Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. Rosiglitazone 11-24 insulin Homo sapiens 82-89 15483106-1 2005 Our objective was to evaluate the effectiveness of the insulin-sensitizing agent rosiglitazone in obese women with polycystic ovary syndrome (PCOS) and severe insulin resistance. Rosiglitazone 81-94 insulin Homo sapiens 55-62 15483106-1 2005 Our objective was to evaluate the effectiveness of the insulin-sensitizing agent rosiglitazone in obese women with polycystic ovary syndrome (PCOS) and severe insulin resistance. Rosiglitazone 81-94 insulin Homo sapiens 159-166 15483106-10 2005 After treatment with rosiglitazone, there were significant decreases in fasting insulin levels (46.0 +/- 6.5 vs. 16.9 +/- 2.0 microU/ml; P < 0.001), insulin AUC (749.3 +/- 136.3 vs. 225.0 +/- 15.7 microU/ml; P = 0.003), fasting glucose levels (90.8 +/- 3.0 vs. 81.8 +/- 1.9 mg/dl; P = 0.003), and glucose AUC (437.9 +/- 25.0 vs. 322.5 +/- 14.7 mg/dl; P < 0.001). Rosiglitazone 21-34 insulin Homo sapiens 80-87 15483106-15 2005 We conclude that 1) rosiglitazone therapy improves insulin resistance and glucose tolerance in obese women with PCOS; 2) rosiglitazone decreases ovarian androgen production, which appears to be independent of any changes in LH levels; 3) hyperinsulinemia appears to play a key role in the overproduction of ovarian androgens in these women because attenuation of insulin levels is associated with decreased testosterone levels; and 4) short-term rosiglitazone therapy helps restore spontaneous ovulation. Rosiglitazone 20-33 insulin Homo sapiens 51-58 15483106-15 2005 We conclude that 1) rosiglitazone therapy improves insulin resistance and glucose tolerance in obese women with PCOS; 2) rosiglitazone decreases ovarian androgen production, which appears to be independent of any changes in LH levels; 3) hyperinsulinemia appears to play a key role in the overproduction of ovarian androgens in these women because attenuation of insulin levels is associated with decreased testosterone levels; and 4) short-term rosiglitazone therapy helps restore spontaneous ovulation. Rosiglitazone 121-134 insulin Homo sapiens 243-250 15483106-15 2005 We conclude that 1) rosiglitazone therapy improves insulin resistance and glucose tolerance in obese women with PCOS; 2) rosiglitazone decreases ovarian androgen production, which appears to be independent of any changes in LH levels; 3) hyperinsulinemia appears to play a key role in the overproduction of ovarian androgens in these women because attenuation of insulin levels is associated with decreased testosterone levels; and 4) short-term rosiglitazone therapy helps restore spontaneous ovulation. Rosiglitazone 121-134 insulin Homo sapiens 243-250 15614340-5 2004 It is hypothesized that the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone will improve endothelium-dependent vasodilation, and that this effect will be related to improvements in insulin sensitivity, with concomitant reductions in whole-body insulin resistance. Rosiglitazone 85-98 insulin Homo sapiens 204-211 15614340-5 2004 It is hypothesized that the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone will improve endothelium-dependent vasodilation, and that this effect will be related to improvements in insulin sensitivity, with concomitant reductions in whole-body insulin resistance. Rosiglitazone 85-98 insulin Homo sapiens 267-274 16114542-0 2004 [Effects of rosiglitazone on serum leptin and insulin resistance in patients with Type 2 diabetes]. Rosiglitazone 12-25 insulin Homo sapiens 46-53 15569129-0 2004 Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Rosiglitazone 106-119 insulin Homo sapiens 15-22 15569129-10 2004 RESULTS: Rosiglitazone increased insulin-stimulated myocardial glucose uptake by 38% (from 38.7 +/- 3.4 to 53.3 +/- 3.6 micromol 100 g(-1) min(-1), P = 0.004) and whole body glucose uptake by 36% (P = 0.01), while metformin treatment had no significant effect on myocardial (40.5 +/- 3.5 vs. 36.6 +/- 5.2, NS) or whole body glucose uptake. Rosiglitazone 9-22 insulin Homo sapiens 33-40 15569129-15 2004 CONCLUSIONS: In addition to the improvement in whole body insulin sensitivity, rosiglitazone treatment enhances insulin stimulated myocardial glucose uptake in patients with Type 2 diabetes, most probably due to its suppression of the serum FFAs. Rosiglitazone 79-92 insulin Homo sapiens 58-65 15569129-15 2004 CONCLUSIONS: In addition to the improvement in whole body insulin sensitivity, rosiglitazone treatment enhances insulin stimulated myocardial glucose uptake in patients with Type 2 diabetes, most probably due to its suppression of the serum FFAs. Rosiglitazone 79-92 insulin Homo sapiens 112-119 15579757-0 2004 Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. Rosiglitazone 0-13 insulin Homo sapiens 54-64 15579757-0 2004 Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. Rosiglitazone 0-13 insulin Homo sapiens 73-83 15579757-0 2004 Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. Rosiglitazone 0-13 insulin Homo sapiens 57-64 15579757-2 2004 An objective of the present studies was to assess the effects of the thiazolidinedione insulin sensitizer, rosiglitazone, on indirect markers of beta-cell function and cardiovascular risk in people with type 2 diabetes by measuring plasma PI and the PI:IRI ratio. Rosiglitazone 107-120 insulin Homo sapiens 87-94 15579757-2 2004 An objective of the present studies was to assess the effects of the thiazolidinedione insulin sensitizer, rosiglitazone, on indirect markers of beta-cell function and cardiovascular risk in people with type 2 diabetes by measuring plasma PI and the PI:IRI ratio. Rosiglitazone 107-120 insulin Homo sapiens 250-252 15579757-4 2004 Treatment with rosiglitazone for 26 wk (study 1) produced significant dose-dependent decreases in both plasma PI concentrations (18-29%) and the PI:IRI ratio compared with baseline (7-14%) and placebo (19-29%) (P < 0.001). Rosiglitazone 15-28 insulin Homo sapiens 110-112 15579757-4 2004 Treatment with rosiglitazone for 26 wk (study 1) produced significant dose-dependent decreases in both plasma PI concentrations (18-29%) and the PI:IRI ratio compared with baseline (7-14%) and placebo (19-29%) (P < 0.001). Rosiglitazone 15-28 insulin Homo sapiens 145-147 15579757-6 2004 In study 2, rosiglitazone also significantly reduced both plasma PI and the PI:IRI ratio compared with baseline (P < 0.001). Rosiglitazone 12-25 insulin Homo sapiens 65-67 15579757-6 2004 In study 2, rosiglitazone also significantly reduced both plasma PI and the PI:IRI ratio compared with baseline (P < 0.001). Rosiglitazone 12-25 insulin Homo sapiens 76-78 15579757-8 2004 These results show that rosiglitazone and glyburide have differential effects on absolute PI levels and the PI:IRI ratio in people with type 2 diabetes. Rosiglitazone 24-37 insulin Homo sapiens 90-92 15579757-8 2004 These results show that rosiglitazone and glyburide have differential effects on absolute PI levels and the PI:IRI ratio in people with type 2 diabetes. Rosiglitazone 24-37 insulin Homo sapiens 108-110 16114542-1 2004 OBJECTIVE: To investigate the effects of rosiglitazone on serum leptin and insulin resistance (IR) in patients with Type 2 diabetes and to determine the correlation between IR and serum leptin. Rosiglitazone 41-54 insulin Homo sapiens 75-82 16114542-13 2004 Rosiglitazone can reduce FPG level and serum leptin and improve the insulin resistance in patients with Type 2 diabetes. Rosiglitazone 0-13 insulin Homo sapiens 68-75 15277403-7 2004 Rosiglitazone (16 +/- 2 vs. 20 +/- 1 ml.kg(-1).min(-1), P = 0.02) but not metformin increased insulin clearance by 20%. Rosiglitazone 0-13 insulin Homo sapiens 94-101 15504990-8 2004 After 6 months, at the end of the study, there was a significant improvement in acute insulin response to glucose in the rosiglitazone group (+15.3 microIU x ml(-1) x 10 min(-1); P < 0.001) that led to an increase in the disposition index from 0.18 at baseline to 4.18 at 6 months (P = 0.02). Rosiglitazone 121-134 insulin Homo sapiens 86-93 15504990-9 2004 Furthermore, at the end of the study, the proinsulin-to-insulin ratio had decreased in the rosiglitazone group by 36% (P = 0.03) but did not change significantly in the insulin treatment group. Rosiglitazone 91-104 insulin Homo sapiens 42-52 15504990-9 2004 Furthermore, at the end of the study, the proinsulin-to-insulin ratio had decreased in the rosiglitazone group by 36% (P = 0.03) but did not change significantly in the insulin treatment group. Rosiglitazone 91-104 insulin Homo sapiens 45-52 15504990-9 2004 Furthermore, at the end of the study, the proinsulin-to-insulin ratio had decreased in the rosiglitazone group by 36% (P = 0.03) but did not change significantly in the insulin treatment group. Rosiglitazone 91-104 insulin Homo sapiens 56-63 15482765-8 2004 RESULT(S): Frequencies of ovulation were higher after treatment with an insulin-sensitizing drug (ovulations per subject in 6 months: metformin, 3.3; rosiglitazone, 2.4; and combination, 3.4) than with placebo (0.4). Rosiglitazone 150-163 insulin Homo sapiens 72-79 15343508-1 2004 Thirty overweight patients with clinically characterized and biopsy proven nonalcoholic steatohepatitis (NASH) were enrolled in a 48-week treatment trial with rosiglitazone, a peroxisome proliferator-activator receptor (PPAR)-gamma agonist that enhances insulin sensitivity. Rosiglitazone 159-172 insulin Homo sapiens 254-261 15504990-10 2004 CONCLUSIONS: Rosiglitazone, but not insulin, induced a recovery of pancreatic beta-cell function, as evidenced by the restoration of the first-phase insulin response to glucose, improvement in the disposition index, and a decrease in the proinsulin-to-insulin ratio in subjects with type 2 diabetes in whom oral antihyperglycemic therapy failed. Rosiglitazone 13-26 insulin Homo sapiens 149-156 15504990-10 2004 CONCLUSIONS: Rosiglitazone, but not insulin, induced a recovery of pancreatic beta-cell function, as evidenced by the restoration of the first-phase insulin response to glucose, improvement in the disposition index, and a decrease in the proinsulin-to-insulin ratio in subjects with type 2 diabetes in whom oral antihyperglycemic therapy failed. Rosiglitazone 13-26 insulin Homo sapiens 238-248 15504990-10 2004 CONCLUSIONS: Rosiglitazone, but not insulin, induced a recovery of pancreatic beta-cell function, as evidenced by the restoration of the first-phase insulin response to glucose, improvement in the disposition index, and a decrease in the proinsulin-to-insulin ratio in subjects with type 2 diabetes in whom oral antihyperglycemic therapy failed. Rosiglitazone 13-26 insulin Homo sapiens 149-156 15628829-0 2004 Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. Rosiglitazone 59-72 insulin Homo sapiens 95-102 15628829-11 2004 CONCLUSION: More patients were diagnosed with CHF during the 6 months after rosiglitazone was added to their drug regimens than in the previous 6 months, when these patients received insulin but not rosiglitazone. Rosiglitazone 76-89 insulin Homo sapiens 183-190 15529521-0 2004 Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes. Rosiglitazone 30-43 insulin Homo sapiens 58-65 15529521-2 2004 Metformin (a biguanide) and rosiglitazone (a thiazolidinedione) counter insulin resistance, acting by different cellular mechanisms. Rosiglitazone 28-41 insulin Homo sapiens 72-79 15311106-0 2004 Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. Rosiglitazone 42-55 insulin Homo sapiens 132-139 15311106-3 2004 OBJECTIVE: To determine the effect of the thiazolidinedione rosiglitazone on BP and insulin resistance in patients with type 2 diabetes and hypertension. Rosiglitazone 60-73 insulin Homo sapiens 84-91 15311106-6 2004 RESULTS: Insulin sensitivity estimated with the clamp significantly increased (Mbw/I index changed from 33.9 +/- 2.6 to 41.9 +/- 3.2 micromol/min per kg per nmol/l, P < 0.001) and the HOMA-IR index significantly decreased (6.34 +/- 0.39 versus 4.40 +/- 0.33, P < 0.001) during rosiglitazone treatment. Rosiglitazone 283-296 insulin Homo sapiens 9-16 15311106-10 2004 CONCLUSIONS: Treatment of type 2 diabetic hypertensive patients with rosiglitazone significantly increased insulin sensitivity and lowered ambulatory BP. Rosiglitazone 69-82 insulin Homo sapiens 107-114 15277403-9 2004 Insulin-stimulated glucose uptake increased significantly with rosiglitazone but not with metformin. Rosiglitazone 63-76 insulin Homo sapiens 0-7 15277403-13 2004 In conclusion, rosiglitazone but not metformin decreases liver fat and increases insulin clearance. Rosiglitazone 15-28 insulin Homo sapiens 81-88 15243303-7 2004 RESULTS: A significant drop in systolic and diastolic blood pressure by 6.1 +/- 4.1 mm Hg and 4.2 +/- 1.9 mm Hg respectively; a reduction in plasma insulin concentration by 4.3 +/- 1.9 mU/L and a decline in skin sympathetic activity were observed in the group receiving ROS. Rosiglitazone 270-273 insulin Homo sapiens 148-155 15243303-10 2004 CONCLUSIONS: Rosiglitazone improved both plasma glucose and blood pressure levels, probably by attenuation of hyperinsulinemia and sympathetic activity, while Glibenclamide worsened blood pressure control possibly by elevation of insulin levels and activation of the sympathetic system. Rosiglitazone 13-26 insulin Homo sapiens 115-122 15510236-5 2004 In patients whose type 2 diabetes is inadequately controlled with metformin monotherapy, the addition of rosiglitazone significantly improves glycemic control, insulin sensitivity and beta-cell function, compared with either drug alone. Rosiglitazone 105-118 insulin Homo sapiens 160-167 15246889-6 2004 Rosiglitazone treatment significantly reduced C-reactive protein (median 0.56 mg/L [interquartile range 0.33 to 1.02] to 0.33 mg/L [interquartile range 0.26 to 0.40], p <0.01), von Willebrand factor (139 +/- 47 to 132 +/- 44 IU/dl, p = 0.02), insulin resistance index (p = 0.05), and mean low-density lipoprotein (LDL) density (p <0.001) compared with placebo. Rosiglitazone 0-13 insulin Homo sapiens 246-253 14749206-2 2004 Rosiglitazone did not increase subcutaneous fat in patients with HAART-associated lipodystrophy (HAL) in a randomized, double-blind, placebo-controlled trial, although it attenuated insulin resistance and decreased liver fat content. Rosiglitazone 0-13 insulin Homo sapiens 182-189 15199366-8 2004 Rosiglitazone treatment significantly reduced the insulin resistance index (HOMA-R) compared with placebo (P =.02). Rosiglitazone 0-13 insulin Homo sapiens 50-57 14749206-9 2004 In conclusion, rosiglitazone induced significant changes in gene expression in subcutaneous adipose tissue and ameliorated insulin resistance in patients with HAL. Rosiglitazone 15-28 insulin Homo sapiens 123-130 14749206-10 2004 Increased expression of adiponectin might have mediated most of the favorable insulin-sensitizing effects of rosiglitazone in these patients. Rosiglitazone 109-122 insulin Homo sapiens 78-85 15161787-7 2004 Insulin sensitivity increased with rosiglitazone (+6 +/- 3 micromol. Rosiglitazone 35-48 insulin Homo sapiens 0-7 15161787-14 2004 CONCLUSIONS: At equivalent glycemic control, rosiglitazone, but not metformin, improves endothelium dependent vasodilatation and insulin sensitivity in type 2 diabetes. Rosiglitazone 45-58 insulin Homo sapiens 129-136 15038907-17 2004 Sensitivity analyses undertaken by the assessment team suggest that the cost per quality-adjusted life-year (QALY) of rosiglitazone is most sensitive to dosage and treatment effect, that is, the effect of rosiglitazone on beta-cell function and insulin sensitivity. Rosiglitazone 118-131 insulin Homo sapiens 245-252 15148065-7 2004 RESULTS: Rosiglitazone, when compared with placebo, improved insulin sensitivity (mean [+/-SD] change, 1.5 +/- 2.1 mg of glucose/kg of lean body mass per minute vs. -0.4 +/- 1.6 mg/kg per minute; P = 0.02), increased adiponectin levels (mean [+/-SD], 2.2 +/- 2.2 micro g/mL vs. 0.1 +/- 1.1 microg/mL; P = 0.006), and reduced free fatty acid levels (mean [+/-SD], -0.09 +/- 0.1 mmol/L vs. 0.01 +/- 0.1 mmol/L; P = 0.02). Rosiglitazone 9-22 insulin Homo sapiens 61-68 15148065-11 2004 CONCLUSIONS: The authors demonstrated positive effects of rosiglitazone on lipoatrophy; insulin sensitivity; and metabolic indices, including adiponectin levels, in HIV-infected patients with lipoatrophy and insulin resistance. Rosiglitazone 58-71 insulin Homo sapiens 208-215 14625208-11 2004 The PPARgamma agonists rosiglitazone and 15-deoxy-Delta-(12,14)prostaglandin J(2) prevented the cytostatic effect of FFA as well as the FFA-induced changes of PPAR and insulin mRNA expression. Rosiglitazone 23-36 insulin Homo sapiens 168-175 15001452-8 2004 Rosiglitazone treatment significantly reduced insulin resistance, estimated by homeostasis model of insulin resistance index, compared with placebo (P=0.01). Rosiglitazone 0-13 insulin Homo sapiens 46-53 15001452-8 2004 Rosiglitazone treatment significantly reduced insulin resistance, estimated by homeostasis model of insulin resistance index, compared with placebo (P=0.01). Rosiglitazone 0-13 insulin Homo sapiens 100-107 15089784-0 2004 Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Rosiglitazone 0-13 insulin Homo sapiens 23-30 15089784-1 2004 AIMS: To determine the effects of rosiglitazone on insulin sensitivity, glucose tolerance and ambulatory blood pressure when administered to subjects with persistent impaired glucose tolerance (IGT). Rosiglitazone 34-47 insulin Homo sapiens 51-58 15089784-5 2004 RESULTS: Rosiglitazone significantly improved the insulin sensitivity index by 2.26 micro g/kg per min per pmol/l relative to placebo (P = 0.0003). Rosiglitazone 9-22 insulin Homo sapiens 50-57 15089784-10 2004 CONCLUSIONS: Consistent with its effects in patients with Type 2 diabetes, rosiglitazone substantially improved whole body insulin sensitivity and the glycaemic and insulinaemic responses to an OGTT and meal tolerance test in subjects with persistent IGT. Rosiglitazone 75-88 insulin Homo sapiens 123-130 15087762-6 2004 Rosiglitazone was added to insulin or glyburide to improve elevated hemoglobin Hb A1C levels in patients with preexisting diabetes or was used to try to avoid insulin therapy in posttransplant diabetics. Rosiglitazone 0-13 insulin Homo sapiens 27-34 15087762-6 2004 Rosiglitazone was added to insulin or glyburide to improve elevated hemoglobin Hb A1C levels in patients with preexisting diabetes or was used to try to avoid insulin therapy in posttransplant diabetics. Rosiglitazone 0-13 insulin Homo sapiens 159-166 14759393-2 2004 Compared with those receiving placebo, patients in the rosiglitazone group achieved significant reductions in fasting plasma insulin levels (-40%), homeostasis model assessment indexes (-45%), systolic and diastolic blood pressures, and high-sensitivity C-reactive protein levels (-31%). Rosiglitazone 55-68 insulin Homo sapiens 125-132 15037412-0 2004 Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Rosiglitazone 10-23 insulin Homo sapiens 27-34 15037412-1 2004 OBJECTIVE: To evaluate the effects of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome (PCOS). Rosiglitazone 38-51 insulin Homo sapiens 55-62 15037412-14 2004 CONCLUSION(S): Associated with the decrease in LH, rosiglitazone improved insulin-resistance parameters and normalized the menstrual cycle, which suggests that this drug could improve the endocrine-reproductive condition in insulin-resistant women with PCOS. Rosiglitazone 51-64 insulin Homo sapiens 74-81 15037412-14 2004 CONCLUSION(S): Associated with the decrease in LH, rosiglitazone improved insulin-resistance parameters and normalized the menstrual cycle, which suggests that this drug could improve the endocrine-reproductive condition in insulin-resistant women with PCOS. Rosiglitazone 51-64 insulin Homo sapiens 224-231 15130377-10 2004 CONCLUSION: Rosiglitazone therapy improves insulin sensitivity and ovulation induction. Rosiglitazone 12-25 insulin Homo sapiens 43-50 16145910-0 2004 [Effect of rosiglitazone on level of serum TNF-alpha and its relation with insulin resistance in type 2 diabetes mellitus]. Rosiglitazone 11-24 insulin Homo sapiens 75-82 16145910-6 2004 CONCLUSION: Rosiglitazone can decrease the level of serum TNF-alpha significantly and improve insulin resistance. Rosiglitazone 12-25 insulin Homo sapiens 94-101 15120703-2 2004 Thiazolidinediones (TZDs), such as rosiglitazone, are a class of oral antidiabetic agents that act primarily as insulin sensitisers, reducing insulin resistance with associated improvements in glycemic control. Rosiglitazone 35-48 insulin Homo sapiens 112-119 15120703-2 2004 Thiazolidinediones (TZDs), such as rosiglitazone, are a class of oral antidiabetic agents that act primarily as insulin sensitisers, reducing insulin resistance with associated improvements in glycemic control. Rosiglitazone 35-48 insulin Homo sapiens 142-149 14671216-9 2003 RSG (10 nM) reduced the insulin-mediated rise in resistin protein secretion (1 nM insulin plus RSG, 971 +/- 35 pg/ml; insulin, 1 microM insulin plus RSG, 1019 +/- 28 pg/ml; P < 0.01 vs. insulin alone). Rosiglitazone 0-3 insulin Homo sapiens 24-31 14747233-0 2004 In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Rosiglitazone 20-33 insulin Homo sapiens 46-53 14747233-14 2004 Rosiglitazone ameliorated insulin resistance by 60% compared with nateglinide. Rosiglitazone 0-13 insulin Homo sapiens 26-33 14747233-16 2004 Coinfusion of exogenous insulin increased ACh response further in the rosiglitazone group. Rosiglitazone 70-83 insulin Homo sapiens 24-31 14747233-20 2004 Both endothelial dysfunction and insulin resistance are amenable to treatment by rosiglitazone. Rosiglitazone 81-94 insulin Homo sapiens 33-40 14556646-1 2004 Peroxisome-proliferator-activated receptor gamma agonists such as rosiglitazone, a thiazolidinedione, improve insulin sensitivity in vivo, but the underlying mechanism(s) remains unclear. Rosiglitazone 66-79 insulin Homo sapiens 110-117 14556646-3 2004 In the present study, we investigated whether rosiglitazone improves insulin sensitivity by decreasing IRS1 inhibitory serine phosphorylation. Rosiglitazone 46-59 insulin Homo sapiens 69-76 14556646-4 2004 In HEK-293 (human embryonic kidney 293) cells stably expressing recombinant IRS1 and in 3T3L1 adipocytes, rosiglitazone attenuated PMA-induced IRS1 S307/S612 phosphorylation and decreased insulin-stimulated Akt phosphorylation. Rosiglitazone 106-119 insulin Homo sapiens 188-195 14556646-6 2004 Treatment with rosiglitazone at 30 mg/kg body weight for 24 and 48 h increased insulin signalling and decreased IRS1 S307 phosphorylation concomitantly. Rosiglitazone 15-28 insulin Homo sapiens 79-86 14556646-9 2004 Taken together, these results suggest that IRS1 inhibitory serine phosphorylation is a key component of insulin resistance and its reversal contributes to the insulin sensitizing effects by rosiglitazone. Rosiglitazone 190-203 insulin Homo sapiens 159-166 15641698-0 2004 Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance. Rosiglitazone 10-23 insulin Homo sapiens 122-129 15641698-2 2004 Twenty-five patients diagnosed as having polycystic ovary syndrome (PCOS) combined with insulin resistance were treated with rosiglitazone for 12 weeks. Rosiglitazone 125-138 insulin Homo sapiens 88-95 15641698-8 2004 It is likely that reduction of hyperinsulinemia that is produce by rosiglitazone may effectively improve the endocrine, metabolism and ovulatory performance in the patients with PCOS and insulin resistance. Rosiglitazone 67-80 insulin Homo sapiens 36-43 14624133-5 2003 The peroxisome proliferator-activated receptor-gamma agonists, the thiazolidinediones, pioglitazone and rosiglitazone, are insulin sensitizing agents, that are licensed for the management of hyperglycaemia. Rosiglitazone 104-117 insulin Homo sapiens 123-130 14679177-6 2003 Upon treatment with rosiglitazone, an insulin-sensitizing drug, these macrophage-originated genes are downregulated. Rosiglitazone 20-33 insulin Homo sapiens 38-45 14671216-9 2003 RSG (10 nM) reduced the insulin-mediated rise in resistin protein secretion (1 nM insulin plus RSG, 971 +/- 35 pg/ml; insulin, 1 microM insulin plus RSG, 1019 +/- 28 pg/ml; P < 0.01 vs. insulin alone). Rosiglitazone 0-3 insulin Homo sapiens 82-89 14671216-9 2003 RSG (10 nM) reduced the insulin-mediated rise in resistin protein secretion (1 nM insulin plus RSG, 971 +/- 35 pg/ml; insulin, 1 microM insulin plus RSG, 1019 +/- 28 pg/ml; P < 0.01 vs. insulin alone). Rosiglitazone 0-3 insulin Homo sapiens 82-89 14671216-12 2003 In human abdominal sc adipocytes, RSG blocks the insulin-mediated release of resistin secretion in vitro. Rosiglitazone 34-37 insulin Homo sapiens 49-56 14520628-3 2003 The aim of the study is to investigate the effects of rosiglitazone (ROS), an insulin sensitizer, on glucose metabolism in CAPD patients without diabetes. Rosiglitazone 54-67 insulin Homo sapiens 78-85 14642684-8 2003 RESULTS: Rosiglitazone treatment resulted in a significant reduction in E-selectin (p = 0.03), von Willebrand factor (p = 0.007), C-reactive protein (p < 0.001), fibrinogen (p = 0.003) and the homeostasis model of insulin resistance index (p = 0.02), compared with placebo. Rosiglitazone 9-22 insulin Homo sapiens 217-224 14642684-10 2003 Within the rosiglitazone-treated group, reductions in C-reactive protein and von Willebrand factor were significantly correlated with a reduction in insulin resistance. Rosiglitazone 11-24 insulin Homo sapiens 149-156 14520628-3 2003 The aim of the study is to investigate the effects of rosiglitazone (ROS), an insulin sensitizer, on glucose metabolism in CAPD patients without diabetes. Rosiglitazone 69-72 insulin Homo sapiens 78-85 14520628-14 2003 CONCLUSION: ROS improved insulin resistance in CAPD patients without diabetes. Rosiglitazone 12-15 insulin Homo sapiens 25-32 12882907-0 2003 Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Rosiglitazone 175-188 insulin Homo sapiens 39-46 14669724-2 2003 A large case-control study finds that lipoatrophy is the predominant fat abnormality in HIV-infected patients, and a small randomized, placebo-controlled study finds benefit for rosiglitazone for insulin resistance. Rosiglitazone 178-191 insulin Homo sapiens 196-203 12957323-10 2003 Rosiglitazone, an agent with insulin-sensitizing properties, decreases PAI-1 and CRP levels. Rosiglitazone 0-13 insulin Homo sapiens 29-36 12866663-7 2003 Thiazolidinediones, such as rosiglitazone that act primarily as insulin sensitisers, have a profound anti-inflammatory and potentially antiatherosclerotic activity. Rosiglitazone 28-41 insulin Homo sapiens 64-71 14512888-13 2003 In conclusion, improving insulin sensitivity with rosiglitazone resulted in improved histologic markers of NASH, an observation suggesting that insulin resistance contributes to its development and that improving insulin sensitivity may be important in treating this liver disease. Rosiglitazone 50-63 insulin Homo sapiens 144-151 14512888-13 2003 In conclusion, improving insulin sensitivity with rosiglitazone resulted in improved histologic markers of NASH, an observation suggesting that insulin resistance contributes to its development and that improving insulin sensitivity may be important in treating this liver disease. Rosiglitazone 50-63 insulin Homo sapiens 144-151 12940867-0 2003 Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Rosiglitazone 0-13 insulin Homo sapiens 27-34 12940867-1 2003 OBJECTIVE: The aim of this study was to investigate the effect of insulin and an insulin-sensitizing agent, rosiglitazone (RSG), on the production of plasminogen-activator inhibitor-1 (PAI-1) in isolated subcutaneous abdominal adipocytes. Rosiglitazone 108-121 insulin Homo sapiens 81-88 12940867-1 2003 OBJECTIVE: The aim of this study was to investigate the effect of insulin and an insulin-sensitizing agent, rosiglitazone (RSG), on the production of plasminogen-activator inhibitor-1 (PAI-1) in isolated subcutaneous abdominal adipocytes. Rosiglitazone 123-126 insulin Homo sapiens 81-88 12954157-3 2003 We investigated the effect of the insulin-sensitizing antidiabetic agent rosiglitazone at a dose level of 8 mg/day on in vivo skin nitric oxide (NO) production and blood flow in the foot in a 16-week, randomized, double-blind, placebo-controlled crossover to open-label, single-blind study in patients with T2DM. Rosiglitazone 73-86 insulin Homo sapiens 34-41 12878365-13 2003 Because rosiglitazone improves insulin receptor sensitivity (IRS), it is logical to assume that the reduction in hyperinsulinemia reflects improvement in IRS. Rosiglitazone 8-21 insulin Homo sapiens 31-38 12882907-7 2003 The insulin sensitizer rosiglitazone improved insulin-stimulated IRS-1-dependent PI 3-kinase and aPKC activation, as well as glucose disposal rates. Rosiglitazone 23-36 insulin Homo sapiens 4-11 12882907-7 2003 The insulin sensitizer rosiglitazone improved insulin-stimulated IRS-1-dependent PI 3-kinase and aPKC activation, as well as glucose disposal rates. Rosiglitazone 23-36 insulin Homo sapiens 46-53 12882909-0 2003 Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Rosiglitazone 0-13 insulin Homo sapiens 34-41 12882909-4 2003 RSG improved fasting plasma glucose (185 +/- 8 to 139 +/- 5 mg/dl), mean plasma glucose during the OGTT (290 +/- 9 to 225 +/- 6 mg/dl), HbA(1c) (8.5 +/- 0.3 to 7.1 +/- 0.3%), insulin-mediated total-body glucose disposal (TGD) (6.9 +/- 0.7 to 9.2 +/- 0.8 mg x kg(-1) fat-free mass x min(-1)) (all P < 0.001), and decreased fasting plasma free fatty acid (FFA) (789 +/- 59 to 656 +/- 50 micro Eq/l) and mean FFA during the OGTT (644 +/- 41 to 471 +/- 35 micro Eq/l) (both P < 0.01). Rosiglitazone 0-3 insulin Homo sapiens 175-182 12620440-17 2003 For all subjects, fasting insulin declined from 29.4 +/- 13.8 microU/mL to 17.3 +/- 7.8 microU/mL after rosiglitazone (P=.003, paired t-test). Rosiglitazone 104-117 insulin Homo sapiens 26-33 12681023-0 2003 Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Rosiglitazone 12-25 insulin Homo sapiens 67-74 12681023-1 2003 AIM: These analyses were undertaken to evaluate the efficacy of the insulin sensitizer rosiglitazone (RSG) when added to the therapy of obese type 2 diabetes mellitus patients (T2DM) taking near-maximal doses (2.5 g/day) of metformin (MET). Rosiglitazone 87-100 insulin Homo sapiens 68-75 12681023-1 2003 AIM: These analyses were undertaken to evaluate the efficacy of the insulin sensitizer rosiglitazone (RSG) when added to the therapy of obese type 2 diabetes mellitus patients (T2DM) taking near-maximal doses (2.5 g/day) of metformin (MET). Rosiglitazone 102-105 insulin Homo sapiens 68-75 12681023-8 2003 CONCLUSIONS: In obese type 2 diabetic patients inadequately controlled on MET alone, addition of rosiglitazone improves glycaemic control, insulin sensitivity and beta-cell function to a clinically important extent. Rosiglitazone 97-110 insulin Homo sapiens 139-146 12924536-9 2003 However, rosiglitazone decreased % liver fat (spectroscopy) and serum insulin concentrations, and normalized liver function tests. Rosiglitazone 9-22 insulin Homo sapiens 70-77 12924536-12 2003 Rosiglitazone seemed to ameliorate insulin resistance judged by the decreased serum insulin concentrations and % liver fat. Rosiglitazone 0-13 insulin Homo sapiens 35-42 12924536-12 2003 Rosiglitazone seemed to ameliorate insulin resistance judged by the decreased serum insulin concentrations and % liver fat. Rosiglitazone 0-13 insulin Homo sapiens 84-91 12752488-10 2003 CONCLUSION: Rosiglitazone improved insulin sensitivity, pancreatic beta-cell function, and glycaemic control in Indo-Asian patients with Type 2 DM who are at greater risk of the complications of Type 2 DM than other ethnic groups. Rosiglitazone 12-25 insulin Homo sapiens 35-42 12615670-10 2003 Rosiglitazone decreased LFAT, serum insulin, and plasma PAI-1 and increased serum triglycerides but had no effect on intra-abdominal or subcutaneous fat mass or PAI-1 mRNA. Rosiglitazone 0-13 insulin Homo sapiens 36-43 12615670-12 2003 Rosiglitazone decreases LFAT, serum insulin, and plasma PAI-1 without changing the size of other fat depots or PAI-1 mRNA in subcutaneous fat. Rosiglitazone 0-13 insulin Homo sapiens 36-43 12663234-0 2003 Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. Rosiglitazone 90-103 insulin Homo sapiens 107-114 12663234-2 2003 The aims of this pilot study were to examine the safety of using the insulin-sensitizing peroxisomal proliferator activated receptor (PPAR) gamma ligand rosiglitazone in patients with NASH and determine whether improved insulin sensitivity correlates with improved fatty liver. Rosiglitazone 153-166 insulin Homo sapiens 69-76 12663234-5 2003 RESULTS: By 24 weeks, rosiglitazone improved insulin sensitivity and reduced liver fat content. Rosiglitazone 22-35 insulin Homo sapiens 45-52 12663234-9 2003 CONCLUSIONS: Treatment of NASH with rosiglitazone for 24 weeks improved insulin sensitivity, reduced liver fat content and improved biochemical evidence of hepatocellular injury. Rosiglitazone 36-49 insulin Homo sapiens 72-79 12620440-22 2003 Rosiglitazone therapy improves insulin sensitivity and decreases hyperandrogenemia primarily through increases in SHBG. Rosiglitazone 0-13 insulin Homo sapiens 31-38 12540598-5 2003 Rosiglitazone improved insulin-stimulated whole-body glucose uptake by 44% (P < 0.01 vs. placebo). Rosiglitazone 0-13 insulin Homo sapiens 23-30 12566086-7 2003 Thus, the inhibition of cytokine-induced NO synthesis by rosiglitazone is at least in part attributable to reduced availability of BH4, the synthesis of which might represent a potential new target in the treatment of type 2 diabetes and insulin resistance. Rosiglitazone 57-70 insulin Homo sapiens 238-245 12540598-11 2003 The improved insulin sensitivity of the nonabdominal subcutaneous adipose tissue during treatment with rosiglitazone partly explains the enhanced whole-body insulin sensitivity and underlies the central role of adipose tissue for action of peroxisome proliferator-activated receptor gamma agonist in vivo. Rosiglitazone 103-116 insulin Homo sapiens 13-20 12540598-11 2003 The improved insulin sensitivity of the nonabdominal subcutaneous adipose tissue during treatment with rosiglitazone partly explains the enhanced whole-body insulin sensitivity and underlies the central role of adipose tissue for action of peroxisome proliferator-activated receptor gamma agonist in vivo. Rosiglitazone 103-116 insulin Homo sapiens 157-164 14553866-6 2003 In particular, information on insulin-sensitizing agents-metformin and the currently available thiazolidinediones (TZDs), pioglitazone and rosiglitazone-is presented. Rosiglitazone 139-152 insulin Homo sapiens 30-37 12593999-0 2003 Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. Rosiglitazone 95-108 insulin Homo sapiens 14-21 12593999-8 2003 RESULTS: Combined rosiglitazone and clomiphene treatment led to a significant reduction in area under the insulin curve (AUC insulin), whereas clomiphene monotherapy did not lead to this reduction. Rosiglitazone 18-31 insulin Homo sapiens 106-113 12593999-8 2003 RESULTS: Combined rosiglitazone and clomiphene treatment led to a significant reduction in area under the insulin curve (AUC insulin), whereas clomiphene monotherapy did not lead to this reduction. Rosiglitazone 18-31 insulin Homo sapiens 125-132 12593999-12 2003 CONCLUSION: Combined rosiglitazone and clomiphene was an effective therapeutic regimen for correcting insulin resistance in patients with PCOS, possibly by reducing IGF1 bioavailability to the ovaries, thus modifying the hyperandrogenic intrafollicular milieu that occurs in PCOS. Rosiglitazone 21-34 insulin Homo sapiens 102-109 12917943-0 2003 Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Rosiglitazone 52-65 insulin Homo sapiens 0-7 12467491-11 2003 The thiazolidinedione rosiglitazone has been shown to have a potent insulin-sensitising action that appears to be mediated through the peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Rosiglitazone 22-35 insulin Homo sapiens 68-75 12502504-7 2003 Rosiglitazone treatment caused a clear reduction of IMCL and hepatic fat despite increased body weight, and a marked improvement of insulin sensitivity. Rosiglitazone 0-13 insulin Homo sapiens 132-139 12502504-8 2003 Thus, the insulin sensitizing properties of rosiglitazone were consistent with a redistribution of lipids from nonadipocytic (skeletal muscle, liver) back into fat tissue. Rosiglitazone 44-57 insulin Homo sapiens 10-17 12502676-0 2003 Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Rosiglitazone 0-13 insulin Homo sapiens 23-30 12466369-8 2002 Furthermore, enhanced adiponectin secretion from fat cells derived from the visceral compartment in response to rosiglitazone alone or in combination with insulin may play a role in some of the systemic insulin-sensitizing and antiinflammatory properties of the thiazolidinediones. Rosiglitazone 112-125 insulin Homo sapiens 203-210 12502676-1 2003 OBJECTIVE: To examine the effect of rosiglitazone on insulin resistance and blood pressure in patients with essential hypertension, classified based on abnormalities of their renin-angiotensin system. Rosiglitazone 36-49 insulin Homo sapiens 53-60 12502676-14 2003 CONCLUSIONS: Rosiglitazone treatment of nondiabetic hypertensive patients improves insulin sensitivity, reduces systolic and diastolic blood pressure, and induces favorable changes in markers of cardiovascular risk. Rosiglitazone 13-26 insulin Homo sapiens 83-90 12825962-6 2003 When given as monotherapy or in combination with sulphonylureas, metformin or insulin in patients with type 2 diabetes, the currently available thiazolidinediones (rosiglitazone and pioglitazone) ameliorate glycaemic control, by lowering fasting and postprandial blood glucose levels, and improve insulin sensitivity in placebo-controlled trials. Rosiglitazone 164-177 insulin Homo sapiens 78-85 12825962-6 2003 When given as monotherapy or in combination with sulphonylureas, metformin or insulin in patients with type 2 diabetes, the currently available thiazolidinediones (rosiglitazone and pioglitazone) ameliorate glycaemic control, by lowering fasting and postprandial blood glucose levels, and improve insulin sensitivity in placebo-controlled trials. Rosiglitazone 164-177 insulin Homo sapiens 297-304 14668701-4 2003 The TZDs rosiglitazone and pioglitazone work mainly by reducing insulin resistance and may have the potential to alter the natural history of type 2 diabetes and reduce the cardiovascular mortality and morbidity associated with this condition. Rosiglitazone 9-22 insulin Homo sapiens 64-71 12453903-0 2002 Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Rosiglitazone 0-13 insulin Homo sapiens 41-48 12453903-1 2002 Rosiglitazone, a thiazolidinedione, enhances peripheral insulin sensitivity in patients with type 2 diabetes. Rosiglitazone 0-13 insulin Homo sapiens 56-63 12453903-11 2002 In conclusion, rosiglitazone but not metformin 1) improves insulin responsiveness in resting skeletal muscle and 2) doubles the insulin-stimulated glucose uptake rate during physical exercise in patients with type 2 diabetes. Rosiglitazone 15-28 insulin Homo sapiens 59-66 12453903-12 2002 Our results suggest that rosiglitazone improves synergic action of insulin and exercise. Rosiglitazone 25-38 insulin Homo sapiens 67-74 12469695-5 2002 (4) Rosiglitazone and pioglitazone (glitazones that reduce insulin resistance) have been authorized in the European Union for combination with a glucose-lowering sulphonylurea (for patients in whom metformin is ineffective or poorly tolerated) or with metformin (for obese patients). Rosiglitazone 4-17 insulin Homo sapiens 59-66 11903029-13 2002 Pharmacological intervention with rosiglitazone enhanced insulin sensitivity and reduced ADMA levels. Rosiglitazone 34-47 insulin Homo sapiens 57-64 12376581-0 2002 Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Rosiglitazone 10-23 insulin Homo sapiens 27-34 12376581-1 2002 OBJECTIVE: To investigate the effects of rosiglitazone (RSG) on insulin sensitivity and regional adiposity (including intrahepatic fat) in patients with type 2 diabetes. Rosiglitazone 41-54 insulin Homo sapiens 64-71 12376581-1 2002 OBJECTIVE: To investigate the effects of rosiglitazone (RSG) on insulin sensitivity and regional adiposity (including intrahepatic fat) in patients with type 2 diabetes. Rosiglitazone 56-59 insulin Homo sapiens 64-71 12376581-2 2002 RESEARCH METHODS AND PROCEDURES: We examined the effect of RSG (8 mg/day, 2 divided doses) compared with placebo on insulin sensitivity and body composition in 33 type 2 diabetic patients. Rosiglitazone 59-62 insulin Homo sapiens 116-123 12376581-4 2002 RESULTS: There was a significant improvement in glycemic control (glycosylated hemoglobin -0.7 +/- 0.7%, p < or = 0.05) and an 86% increase in insulin sensitivity in the RSG group (glucose-disposal rate change from baseline: 17.5 +/- 14.5 micro mol glucose/min/kg free fat mass, p < 0.05), but no significant change in the placebo group compared with baseline. Rosiglitazone 173-176 insulin Homo sapiens 146-153 12376581-7 2002 DISCUSSION: Our data indicate that RSG greatly improves insulin sensitivity in patients with type 2 diabetes and is associated with an increase in adiposity in subcutaneous but not visceral body regions. Rosiglitazone 35-38 insulin Homo sapiens 56-63 12099960-1 2002 AIMS: To evaluate the influence of addition of rosiglitazone to insulin therapy over a 24-week period in massively obese patients with poorly controlled Type 2 diabetes taking large doses of insulin. Rosiglitazone 47-60 insulin Homo sapiens 191-198 12173915-4 2002 RESULTS: After rosiglitazone therapy was instituted, the patient"s insulin dose was gradually tapered and eventually stopped. Rosiglitazone 15-28 insulin Homo sapiens 67-74 12173915-8 2002 Rosiglitazone also helps to counteract the insulin-resistant state and reduces or eliminates the need for exogenous insulin. Rosiglitazone 0-13 insulin Homo sapiens 43-50 12173915-8 2002 Rosiglitazone also helps to counteract the insulin-resistant state and reduces or eliminates the need for exogenous insulin. Rosiglitazone 0-13 insulin Homo sapiens 116-123 11978647-8 2002 Cotreatment with RSG induced an increased dose response to insulin for LPL and HSL (P < 0.05); RSG alone also increased LPL and HSL expression (P < 0.05). Rosiglitazone 17-20 insulin Homo sapiens 59-66 12133398-0 2002 [Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome]. Rosiglitazone 11-24 insulin Homo sapiens 28-35 12133398-1 2002 OBJECTIVE: To evaluate the effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome (PCOS). Rosiglitazone 37-50 insulin Homo sapiens 54-61 12133398-8 2002 CONCLUSION: Rosiglitazone might decrease plasma leptin level and improve insulin sensitivity, which led to alleviation of hyperandrogenism and resumption of ovulation and menses in patients with PCOS. Rosiglitazone 12-25 insulin Homo sapiens 73-80 11903029-5 2002 INTERVENTION: Rosiglitazone (4 mg/d for 4 weeks and then 4 mg twice daily for 8 weeks), an insulin-sensitizing agent, was given to 7 insulin-resistant subjects with hypertension. Rosiglitazone 14-27 insulin Homo sapiens 91-98 11903029-5 2002 INTERVENTION: Rosiglitazone (4 mg/d for 4 weeks and then 4 mg twice daily for 8 weeks), an insulin-sensitizing agent, was given to 7 insulin-resistant subjects with hypertension. Rosiglitazone 14-27 insulin Homo sapiens 133-140 11872682-4 2002 Rosiglitazone treatment resulted in a 68% (P < 0.002) and a 20% (P < 0.016) improvement in insulin-stimulated glucose metabolism during the low- and high- dosage-insulin clamps, respectively, which was associated with approximately 40% reductions in plasma fatty acid concentration (P < 0.05) and hepatic triglyceride content (P < 0.05). Rosiglitazone 0-13 insulin Homo sapiens 97-104 11872682-4 2002 Rosiglitazone treatment resulted in a 68% (P < 0.002) and a 20% (P < 0.016) improvement in insulin-stimulated glucose metabolism during the low- and high- dosage-insulin clamps, respectively, which was associated with approximately 40% reductions in plasma fatty acid concentration (P < 0.05) and hepatic triglyceride content (P < 0.05). Rosiglitazone 0-13 insulin Homo sapiens 168-175 12149047-2 2002 Insulin sensitivity, pancreatic beta-cell function and surrogate markers of cardiovascular risk factors are significantly improved by rosiglitazone. Rosiglitazone 134-147 insulin Homo sapiens 0-7 11881246-3 2002 A case is reported in which a woman with insulin-dependent type-2 diabetes and both macro- and microangiopathy and pronounced insulin resistance was treated with rosiglitazone (Avandia). Rosiglitazone 162-175 insulin Homo sapiens 41-48 12149047-4 2002 Significant decreases in hyperglycaemic markers occurred when rosiglitazone was combined with metformin (HbA(1c) -0.8 to -1.0%), a sulphonylurea (-1.4%) or insulin (-1.2%) for 26 weeks versus little change with active comparator monotherapy. Rosiglitazone 62-75 insulin Homo sapiens 156-163 12149047-16 2002 Rosiglitazone significantly improves insulin sensitivity and, as such, is a welcome addition to the treatment options for patients with type 2 diabetes mellitus. Rosiglitazone 0-13 insulin Homo sapiens 37-44 11560925-9 2001 Treatment of insulin-resistant animals with the insulin sensitizer rosiglitazone restores vessel wall CREB content toward that observed in normal animals. Rosiglitazone 67-80 insulin Homo sapiens 13-20 15832493-2 2002 Insulin sensitivity, pancreatic beta-cell function and surrogate markers of cardiovascular risk factors are significantly improved by rosiglitazone. Rosiglitazone 134-147 insulin Homo sapiens 0-7 15832493-4 2002 Significant decreases in hyperglycemic markers occurred when rosiglitazone was combined with metformin (HbA(1c) -0.8 to -1.0%), a sulfonylurea (-1.4%) or insulin (-1.2%) for 26 weeks versus little change with active comparator monotherapy. Rosiglitazone 61-74 insulin Homo sapiens 154-161 15832493-16 2002 Rosiglitazone significantly improves insulin sensitivity and, as such, is a welcome addition to the treatment options for patients with type 2 diabetes mellitus. Rosiglitazone 0-13 insulin Homo sapiens 37-44 11560925-9 2001 Treatment of insulin-resistant animals with the insulin sensitizer rosiglitazone restores vessel wall CREB content toward that observed in normal animals. Rosiglitazone 67-80 insulin Homo sapiens 48-55 11793023-4 2001 RESULTS: After 12 weeks, rosiglitazone reduced fasting plasma glucose (195 +/- 11 to 150 +/- 7 mg/dl, p < 0.01), mean plasma glucose (PG) during OGTT (293 +/- 12 to 236 +/- 9 mg/dl, p < 0.01), and HbA1 c (8.7 +/- 0.4 to 7.4 +/- 0.3 %, p < 0.01) without changes in plasma insulin concentration. Rosiglitazone 25-38 insulin Homo sapiens 280-287 11793023-11 2001 CONCLUSION/INTERPRETATION: Rosiglitazone increases hepatic and peripheral (muscle) tissue insulin sensitivity and reduces NEFA turnover despite increased total body fat mass. Rosiglitazone 27-40 insulin Homo sapiens 90-97 11561143-8 2001 Improving insulin sensitivity with insulin sensitizers such as rosiglitazone may represent an important advance in our ability to improve vascular dysfunction in diabetes. Rosiglitazone 63-76 insulin Homo sapiens 10-17 11704136-0 2001 Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Rosiglitazone 134-147 insulin Homo sapiens 15-22 11704136-7 2001 RESULT(S): Rosiglitazone treatment for 5 months improved insulin sensitivity, lowered serum free testosterone, and resulted in spontaneous ovulation and conception. Rosiglitazone 11-24 insulin Homo sapiens 57-64 11704136-8 2001 CONCLUSION(S): Rosiglitazone is a promising insulin sensitizer for treatment of PCOS. Rosiglitazone 15-28 insulin Homo sapiens 44-51 11887975-3 2001 OBJECTIVES: To evaluate whether hyperglycaemia in two lean patients with primary severe insulin resistance due to insulin receptor (IR) mutations and diabetes mellitus could be reduced by supplement of rosiglitazone for 180 days and secondary, to evaluate the effects on plasma NEFA, TG, Apo B, PAI-1 and serum insulin. Rosiglitazone 202-215 insulin Homo sapiens 114-121 11887975-14 2001 CONCLUSIONS: Rosiglitazone treatment, in combination with insulin and metformin, of patients with severe primary insulin resistance due to IR mutations and diabetes mellitus, had no impact on the measured estimates of glucose and lipid metabolism. Rosiglitazone 13-26 insulin Homo sapiens 113-120 11887975-0 2001 Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism. Rosiglitazone 0-13 insulin Homo sapiens 49-56 11887975-1 2001 BACKGROUND: Rosiglitazone, a thiazolidinedione (TZD), increases insulin sensitivity by reducing levels of plasma NEFA, triglycerides (TG), glucose and serum insulin. Rosiglitazone 12-25 insulin Homo sapiens 64-71 11887975-2 2001 Rosiglitazone treatment decreases insulin resistance in type 2 diabetic patients, but no data exist concerning rosiglitazone treatment of patients with syndromes of extreme insulin resistance. Rosiglitazone 0-13 insulin Homo sapiens 34-41 11887975-3 2001 OBJECTIVES: To evaluate whether hyperglycaemia in two lean patients with primary severe insulin resistance due to insulin receptor (IR) mutations and diabetes mellitus could be reduced by supplement of rosiglitazone for 180 days and secondary, to evaluate the effects on plasma NEFA, TG, Apo B, PAI-1 and serum insulin. Rosiglitazone 202-215 insulin Homo sapiens 88-95 11712407-1 2001 Rosiglitazone(RSG) is an oral antidiabetic agent of the thiazolidinedion(TDZ) class that exerts its antihyperglycemic effect by reducing insulin resistance. Rosiglitazone 0-13 insulin Homo sapiens 137-144 11712407-1 2001 Rosiglitazone(RSG) is an oral antidiabetic agent of the thiazolidinedion(TDZ) class that exerts its antihyperglycemic effect by reducing insulin resistance. Rosiglitazone 14-17 insulin Homo sapiens 137-144 11712407-4 2001 In animal models of insulin resistance, RSG decreased plasma glucose, triglyceride and insulin levels and also prevented diabetic nephropathy and pancreatic islet cell degeneration. Rosiglitazone 40-43 insulin Homo sapiens 20-27 11712407-4 2001 In animal models of insulin resistance, RSG decreased plasma glucose, triglyceride and insulin levels and also prevented diabetic nephropathy and pancreatic islet cell degeneration. Rosiglitazone 40-43 insulin Homo sapiens 87-94 11579205-5 2001 Rosiglitazone treatment for 48 h significantly increased basal and insulin-stimulated glucose uptake and markedly increased the cellular expression of GLUT1 but not GLUT4. Rosiglitazone 0-13 insulin Homo sapiens 67-74 11579205-6 2001 Rosiglitazone increased plasma membrane levels of GLUT1, but not GLUT4, both basally and after insulin stimulation. Rosiglitazone 0-13 insulin Homo sapiens 95-102 11561143-8 2001 Improving insulin sensitivity with insulin sensitizers such as rosiglitazone may represent an important advance in our ability to improve vascular dysfunction in diabetes. Rosiglitazone 63-76 insulin Homo sapiens 35-42 11715668-3 2001 The second is rosiglitazone, a member of the thiazolidinediones family, which improves the sensitivity of tissues to insulin and reduces insulin resistance. Rosiglitazone 14-27 insulin Homo sapiens 117-124 11560198-1 2001 The thiazolidinedione rosiglitazone maleate works primarily to improve insulin sensitivity in muscle and adipose tissue. Rosiglitazone 22-43 insulin Homo sapiens 71-78 11560198-3 2001 Data using the homeostasis model assessment and proinsulin:insulin ratio in patients with type 2 diabetes mellitus suggest that rosiglitazone may have the potential to sustain or improve beta-cell function. Rosiglitazone 128-141 insulin Homo sapiens 51-58 11560198-5 2001 In clinical trials, rosiglitazone monotherapy significantly reduced glycosylated hemoglobin by 1.5% compared with placebo and led to significant improvements in glycemic control when given in combination with metformin, sulfonylureas, or insulin. Rosiglitazone 20-33 insulin Homo sapiens 238-245 11715668-3 2001 The second is rosiglitazone, a member of the thiazolidinediones family, which improves the sensitivity of tissues to insulin and reduces insulin resistance. Rosiglitazone 14-27 insulin Homo sapiens 137-144 11423507-1 2001 OBJECTIVE: To determine the efficacy and safety of rosiglitazone (RSG) when added to insulin in the treatment of type 2 diabetic patients who are inadequately controlled on insulin monotherapy. Rosiglitazone 51-64 insulin Homo sapiens 173-180 11423507-6 2001 By intent-to-treat analysis, treatment with RSG 8 mg plus insulin resulted in a mean reduction from baseline in HbA(1c) of 1.2% (P < 0.0001), despite a 12% mean reduction of insulin dosage. Rosiglitazone 44-47 insulin Homo sapiens 177-184 11422732-9 2001 Antidiabetic thiazolidinediones (TZDs) such as troglitazone and rosiglitazone are specific ligands of PPARgamma, and this interaction is responsible for the insulin-sensitizing and hypoglycemic effect of these drugs. Rosiglitazone 64-77 insulin Homo sapiens 157-164 11336599-7 2001 Preliminary studies suggest that rosiglitazone also improves glycaemic control in insulin-treated patients while even slightly decreasing insulin dose. Rosiglitazone 33-46 insulin Homo sapiens 82-89 11380072-3 2001 METHODS: The effect of BRL 49653 (Rosiglitazone) on the mRNA expression of insulin receptor, insulin receptor substrate-1, p85alpha, p110alpha and p110beta subunits of phosphatidylinositol 3-kinase, Glut 4 and hormone sensitive lipase was examined in isolated adipocytes. Rosiglitazone 34-47 insulin Homo sapiens 75-82 11380072-3 2001 METHODS: The effect of BRL 49653 (Rosiglitazone) on the mRNA expression of insulin receptor, insulin receptor substrate-1, p85alpha, p110alpha and p110beta subunits of phosphatidylinositol 3-kinase, Glut 4 and hormone sensitive lipase was examined in isolated adipocytes. Rosiglitazone 34-47 insulin Homo sapiens 93-100 11336599-7 2001 Preliminary studies suggest that rosiglitazone also improves glycaemic control in insulin-treated patients while even slightly decreasing insulin dose. Rosiglitazone 33-46 insulin Homo sapiens 138-145 11336599-14 2001 In the treatment of our patients with Type 2 diabetes, drugs like rosiglitazone which directly reduce insulin resistance are very welcome but more data on its combined use with insulin are needed. Rosiglitazone 66-79 insulin Homo sapiens 102-109 11460577-8 2001 Thiazolidinediones (rosiglitazone and pioglitazone) increase the sensitivity of the tissues to insulin. Rosiglitazone 20-33 insulin Homo sapiens 95-102 11160777-7 2001 The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are "insulin sensitizers" and exert direct effects on the mechanisms of insulin resistance. Rosiglitazone 24-37 insulin Homo sapiens 103-110 11160777-7 2001 The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are "insulin sensitizers" and exert direct effects on the mechanisms of insulin resistance. Rosiglitazone 24-37 insulin Homo sapiens 170-177 11965830-10 2000 Another very promising approach is the use of thiazolidinediones (rosiglitazone, pioglitazone) to improve the insulin resistance and possibly preserve the beta cells by reducing the need for increased insulin secretion. Rosiglitazone 66-79 insulin Homo sapiens 110-117 11232013-6 2001 Homeostasis model assessment estimates indicate that rosiglitazone (2 and 4 mg bd) reduced insulin resistance by 16.0% and 24.6%, respectively, and improved ss-cell function over baseline by 49.5% and 60.0%, respectively. Rosiglitazone 53-66 insulin Homo sapiens 91-98 11232013-9 2001 In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions. Rosiglitazone 19-32 insulin Homo sapiens 39-46 11110228-7 2000 Four to 8 mg/d of rosiglitazone given alone or in combination with metformin, sulfonylureas, or insulin has produced reductions in baseline fasting plasma glucose and glycosylated hemoglobin in studies of up to 1 year"s duration. Rosiglitazone 18-31 insulin Homo sapiens 96-103 10859151-0 2000 Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Rosiglitazone 43-56 insulin Homo sapiens 85-92 10859151-1 2000 Rosiglitazone is a potent peroxisome proliferator-activated receptor gamma agonist that decreases hyperglycemia by reducing insulin resistance in patients with type 2 diabetes mellitus. Rosiglitazone 0-13 insulin Homo sapiens 124-131 10707565-1 2000 Rosiglitazone, a thiazolidinedion antidiabetic agent, improves insulin resistance in patients with type 2 diabetes mellitus. Rosiglitazone 0-13 insulin Homo sapiens 63-70 10872292-7 2000 The group of insulin sensitizers includes the biguanide, metformin and the thiazolidinediones or glitazones (rosiglitazone, pioglitazone). Rosiglitazone 109-122 insulin Homo sapiens 13-20 10768088-4 2000 All rosiglitazone treatment groups showed significantly reduced peak postprandial glucose concentrations compared with baseline (p < 0.001) and with placebo (p < 0.0001) and reduced postprandial glucose excursion, without an increase in the area under the postprandial insulin concentration-time curve. Rosiglitazone 4-17 insulin Homo sapiens 275-282 10768088-6 2000 C peptide and serum insulin concentrations were significantly reduced from baseline in all rosiglitazone treatment groups. Rosiglitazone 91-104 insulin Homo sapiens 20-27 10768088-11 2000 CONCLUSION/INTERPRETATION: Rosiglitazone given twice daily significantly reduced fasting and postprandial glucose concentrations, C peptide, insulin and nonesterified fatty acids in Type II diabetic patients. Rosiglitazone 27-40 insulin Homo sapiens 141-148 10707565-3 2000 In animal models of insulin resistence, rosiglitazone decreased plasma glucose, triglyceride and insulin levels and also prevented diabetic nephropathy and pancreatic islet cell degeneration. Rosiglitazone 40-53 insulin Homo sapiens 20-27 10707565-3 2000 In animal models of insulin resistence, rosiglitazone decreased plasma glucose, triglyceride and insulin levels and also prevented diabetic nephropathy and pancreatic islet cell degeneration. Rosiglitazone 40-53 insulin Homo sapiens 97-104 10926309-2 2000 With a focus on clinical efficacy, this paper discusses the results from the 20 major therapeutical trials published in the years 1997-1999, that evaluated the new insulinsensitizing thiazolidinediones Rosiglitazone and Pioglitazone and the new insulin-releasing potassium channel blockers Repaglinide and Nateglinide. Rosiglitazone 202-215 insulin Homo sapiens 164-171 10691158-1 2000 AIMS: This study was designed to test the efficacy and safety of low-dose rosiglitazone, a potent, insulin-sensitizing thiazolidinedione, in combination with sulphonylurea in Type 2 diabetic patients. Rosiglitazone 74-87 insulin Homo sapiens 99-106 10857389-2 2000 Troglitazone, rosiglitazone, and pioglitazone are a new class of oral antidiabetic agents which can ameliorate peripheral insulin resistance in type 2 diabetes. Rosiglitazone 14-27 insulin Homo sapiens 122-129 10577070-1 1999 Rosiglitazone is effective against insulin resistance]. Rosiglitazone 0-13 insulin Homo sapiens 35-42 10605995-3 1999 Acarbose, metformin, miglitol, pioglitazone, rosiglitazone and troglitazone help the patient"s own insulin control glucose levels and allow early treatment with little risk of hypoglycemia. Rosiglitazone 45-58 insulin Homo sapiens 99-106 11139821-6 1999 In clinical studies, rosiglitazone has been shown to be effective, safe and well-tolerated, not only when used as monotherapy, but also when used in combination with sulphonylureas, metformin or insulin. Rosiglitazone 21-34 insulin Homo sapiens 195-202 10400405-1 1999 Rosiglitazone, a thiazolidinedione antidiabetic agent, improves insulin resistance, a key underlying metabolic abnormality in most patients with type 2 (non-insulin-dependent) diabetes mellitus. Rosiglitazone 0-13 insulin Homo sapiens 64-71 10480188-5 1999 A new therapeutic class, the thiazolidinediones (troglitazone, rosiglitazone, pioglitazone) has recently completed the family of insulin-sensitizing agents. Rosiglitazone 63-76 insulin Homo sapiens 129-136 10400405-1 1999 Rosiglitazone, a thiazolidinedione antidiabetic agent, improves insulin resistance, a key underlying metabolic abnormality in most patients with type 2 (non-insulin-dependent) diabetes mellitus. Rosiglitazone 0-13 insulin Homo sapiens 157-164 10400405-2 1999 In animal models of insulin resistance, rosiglitazone decreased plasma glucose, insulin and triglyceride levels and also attenuated or prevented diabetic nephropathy and pancreatic islet cell degeneration. Rosiglitazone 40-53 insulin Homo sapiens 20-27 10400405-2 1999 In animal models of insulin resistance, rosiglitazone decreased plasma glucose, insulin and triglyceride levels and also attenuated or prevented diabetic nephropathy and pancreatic islet cell degeneration. Rosiglitazone 40-53 insulin Homo sapiens 80-87 10400405-6 1999 Addition of rosiglitazone 2 to 8 mg/day to existing sulphonylurea, metformin or insulin therapy achieved further reductions in fasting plasma glucose and HbA1c. Rosiglitazone 12-25 insulin Homo sapiens 80-87 9454824-0 1998 Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. Rosiglitazone 73-86 insulin Homo sapiens 54-61 10226869-11 1999 Because VSMC migration plays an important role in the formation of atherosclerotic lesions and restenosis, PPAR gamma ligands like TRO and RSG, which ameliorate insulin resistance in humans, also may protect the vasculature from diabetes-enhanced injury. Rosiglitazone 139-142 insulin Homo sapiens 161-168 11220287-11 1999 Recent advances in type 2 diabetes therapy have seen the development of the thiazolidinediones (troglitazone, rosiglitazone, and pioglitazone), which improve insulin resistance in patients whose diabetes is poorly controlled by diet and exercise therapy. Rosiglitazone 110-123 insulin Homo sapiens 158-165 11220295-1 1999 AIM: Rosiglitazone is the most potent of the thiazolidinediones, a novel class of oral antidiabetic agents that reduce blood glucose levels by sensitizing peripheral tissues to insulin. Rosiglitazone 5-18 insulin Homo sapiens 177-184 12670479-3 2003 Here we show that insulin-sensitising concentrations of the TZD rosiglitazone partially inhibit serum- or LPS- (but not PMA-) stimulated TNF alpha secretion from primary human monocytes, with an IC(50) of around 50nM. Rosiglitazone 64-77 insulin Homo sapiens 18-25 33609419-8 2021 RESULTS: Treatment with metformin/rosiglitazone in MMTV-ErbB2/Leprdb/db mouse model reduced serum insulin levels, prolonged overall survival, decreased cumulative tumor incidence, and inhibited tumor progression. Rosiglitazone 34-47 insulin Homo sapiens 98-105 34466729-5 2022 Insulin sensitivity recovery was possible with two type 2 diabetes treatments, rosiglitazone and melatonin. Rosiglitazone 79-92 insulin Homo sapiens 0-7 35059243-3 2022 Thiazolidinediones (TZDs) can specifically treat insulin resistance and improve metabolic syndrome, including rosiglitazone, troglitazone and pioglitazone, which are peroxisome proliferator-activated receptor (PPAR) agonists. Rosiglitazone 110-123 insulin Homo sapiens 49-56 35059243-6 2022 Rosiglitazone has been restricted or even withdrawal from the market in most countries owing to concerns about its cardiovascular safety, while its beneficial effect on insulin resistance has been demonstrated. Rosiglitazone 0-13 insulin Homo sapiens 169-176 33115283-2 2021 Rosiglitazone (ROSI), a thiazolidinedione insulin sensitizer, could be used for diabetes with insulin resistance and has been reported to show anticancer effects on human malignant cells. Rosiglitazone 0-13 insulin Homo sapiens 42-49 33115283-2 2021 Rosiglitazone (ROSI), a thiazolidinedione insulin sensitizer, could be used for diabetes with insulin resistance and has been reported to show anticancer effects on human malignant cells. Rosiglitazone 0-13 insulin Homo sapiens 94-101 33115283-2 2021 Rosiglitazone (ROSI), a thiazolidinedione insulin sensitizer, could be used for diabetes with insulin resistance and has been reported to show anticancer effects on human malignant cells. Rosiglitazone 15-19 insulin Homo sapiens 42-49 33115283-2 2021 Rosiglitazone (ROSI), a thiazolidinedione insulin sensitizer, could be used for diabetes with insulin resistance and has been reported to show anticancer effects on human malignant cells. Rosiglitazone 15-19 insulin Homo sapiens 94-101 33115283-7 2021 Both the growth of mouse liver cancer hepatoma H22 cells and serum FBG level in insulin resistant mice were significantly inhibited by combination of ROSI and ADR. Rosiglitazone 150-154 insulin Homo sapiens 80-87 33036752-5 2020 Rosiglitazone (RSG) decreased excessive lipolysis by reducing expression of adipose triglyceride lipase (ATGL) and activity of hormone-sensitive lipase (HSL), which led to decrease of FFA release from insulin-resistant 3T3-L1 adipocytes. Rosiglitazone 0-13 insulin Homo sapiens 201-208 33502690-7 2021 Rosiglitazone, an insulin-sensitizing drug, induced a significant increase of myocardial IR index in obese Zucker rats from 0.96 +- 0.18 to 2.26 +- 0.44 (P<.05) after 7 days of an oral treatment, and 6DIG IR indexes correlated with the gold standard IR index obtained through the hyperinsulinemic-euglycemic clamp (r=.68, P<.02). Rosiglitazone 0-13 insulin Homo sapiens 18-25 33382528-9 2021 CONCLUSION: These results suggest that insulin sensitizer therapy with rosiglitazone improved age- and AD-related learning and memory deficits in circuit selective ways. Rosiglitazone 71-84 insulin Homo sapiens 39-46 33036752-5 2020 Rosiglitazone (RSG) decreased excessive lipolysis by reducing expression of adipose triglyceride lipase (ATGL) and activity of hormone-sensitive lipase (HSL), which led to decrease of FFA release from insulin-resistant 3T3-L1 adipocytes. Rosiglitazone 15-18 insulin Homo sapiens 201-208 33036752-6 2020 Meanwhile, insulin resistance in C2C12 myotubes cocultured with insulin-resistant 3T3-L1 adipocytes was ameliorated after RSG treatment. Rosiglitazone 122-125 insulin Homo sapiens 11-18 33036752-6 2020 Meanwhile, insulin resistance in C2C12 myotubes cocultured with insulin-resistant 3T3-L1 adipocytes was ameliorated after RSG treatment. Rosiglitazone 122-125 insulin Homo sapiens 64-71 32766764-3 2020 In addition, the insulin-sensitizing thiazolidinediones, such as rosiglitazone, are potent and specific activators of PPARgamma. Rosiglitazone 65-78 insulin Homo sapiens 17-24 32344313-6 2020 Our hypothesis is that drugs belonging to the family of thiazolidinediones (TZD) such as pioglitazone or rosiglitazone, approved for treating the condition of insulin resistance and the accompanying inflammation, could ameliorate the prognosis of those COVID-19 patients with diabetes, hypertension and cardiovascular disorders comorbidities. Rosiglitazone 105-118 insulin Homo sapiens 159-166 33643468-12 2021 Testing with rosiglitazone showed a significant improvement in insulin sensitivity and fatty acid metabolism as suggested by previous reports. Rosiglitazone 13-26 insulin Homo sapiens 63-70 30964707-7 2019 Treatment with the insulin sensitizer PPARgamma agonist rosiglitazone in patients with T2DM and CAD is associated with a worsening in aerobic exercise capacity, which seems to be mainly attributable to weight gain and subcutaneous fat mass expansion. Rosiglitazone 56-69 insulin Homo sapiens 19-26 31129998-1 2019 Background Thiazolidinediones (rosiglitazone, pioglitazone) are oral insulin-sensitizing medications used in type 2 diabetes mellitus that reduce glucose with minimal risk of hypoglycemia and potential benefits on atherosclerosis. Rosiglitazone 31-44 insulin Homo sapiens 69-76 30119183-3 2018 Rosiglitazone (RSG), an insulin-sensitizer, is also a synthetic ligand and applied clinically to cure the patients with type 2 diabetes mellitus. Rosiglitazone 0-13 insulin Homo sapiens 24-31 31073335-0 2019 Effect of rosiglitazone on inflammatory cytokines and oxidative stress after intensive insulin therapy in patients with newly diagnosed type 2 diabetes. Rosiglitazone 10-23 insulin Homo sapiens 87-94 31270305-5 2019 Additionally, the linking between the pathological proteins and the insulin signaling mediated by METH in the present work was verified by the treatment with the insulin signaling enhancer rosiglitazone, which was shown to improve the insulin signaling and decrease APP and p-tau expression. Rosiglitazone 189-202 insulin Homo sapiens 68-75 31270305-5 2019 Additionally, the linking between the pathological proteins and the insulin signaling mediated by METH in the present work was verified by the treatment with the insulin signaling enhancer rosiglitazone, which was shown to improve the insulin signaling and decrease APP and p-tau expression. Rosiglitazone 189-202 insulin Homo sapiens 162-169 31270305-5 2019 Additionally, the linking between the pathological proteins and the insulin signaling mediated by METH in the present work was verified by the treatment with the insulin signaling enhancer rosiglitazone, which was shown to improve the insulin signaling and decrease APP and p-tau expression. Rosiglitazone 189-202 insulin Homo sapiens 162-169 30551378-9 2019 Additionally, we noticed that the therapeutic effects of YMS was similar as rosiglitazone, a well-recognized insulin sensitizer. Rosiglitazone 76-89 insulin Homo sapiens 109-116 30278161-1 2018 Rosiglitazone (ROSI), a member of thiazolidinediones (TZDs) which act as high-affinity agonists of the nuclear receptor peroxisome-proliferator-activated receptor-gamma (PPARgamma), is clinically used as an antidiabetic drug which could attenuate the insulin resistance associated with obesity, hypertension, and impaired glucose tolerance in humans. Rosiglitazone 0-13 insulin Homo sapiens 251-258 30278161-1 2018 Rosiglitazone (ROSI), a member of thiazolidinediones (TZDs) which act as high-affinity agonists of the nuclear receptor peroxisome-proliferator-activated receptor-gamma (PPARgamma), is clinically used as an antidiabetic drug which could attenuate the insulin resistance associated with obesity, hypertension, and impaired glucose tolerance in humans. Rosiglitazone 15-19 insulin Homo sapiens 251-258 30119183-3 2018 Rosiglitazone (RSG), an insulin-sensitizer, is also a synthetic ligand and applied clinically to cure the patients with type 2 diabetes mellitus. Rosiglitazone 15-18 insulin Homo sapiens 24-31 29573098-1 2018 AIMS: We aimed to determine the effect of 1-year treatment with the insulin sensitizer peroxisome proliferator-activated receptor (PPAR)-gamma agonist rosiglitazone on exercise capacity and blood pressure (BP) response to exercise in men with coronary artery disease (CAD) and type 2 diabetes (T2D). Rosiglitazone 151-164 insulin Homo sapiens 68-75 29573098-11 2018 CONCLUSIONS: The insulin sensitizer rosiglitazone has a beneficial effect on resting and BP response to exercise in men with CAD and T2D, especially in those with an exaggerated BP response to exercise. Rosiglitazone 36-49 insulin Homo sapiens 17-24 28986164-14 2018 CONCLUSION: Serum ApoJ levels are closely correlated with the magnitude of insulin resistance regardless of obesity, and decrease along with improvement of insulin resistance in response only to rosiglitazone in type 2 diabetes. Rosiglitazone 195-208 insulin Homo sapiens 156-163 29183107-0 2017 Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Rosiglitazone 38-51 insulin Homo sapiens 0-7 28952262-5 2017 The results showed that piperine, rosiglitazone and AMPK agonist AICAR could significantly elevate the glucose consumption in insulin resistance cell models, enhance the level of APN, promote APN mRNA transcripts and increase the protein expression of Adipo receptor. Rosiglitazone 34-47 insulin Homo sapiens 126-133 29228555-13 2017 Metformin or rosiglitazone led to a reduction of betatrophin expression in insulin-stimulated hepatocytes. Rosiglitazone 13-26 insulin Homo sapiens 75-82 28790390-4 2017 In the present study, we identified significant insulin signaling disturbances in the SH-SY5Y cell line that were mediated by BPA, including the inhibition of physiological p-IR Tyr1355 tyrosine, p-IRS1 tyrosine 896, p-AKT serine 473 and p-GSK3alpha/beta serine 21/9 phosphorylation, as well as the enhancement of IRS1 Ser307 phosphorylation; these effects were clearly attenuated by insulin and rosiglitazone. Rosiglitazone 396-409 insulin Homo sapiens 48-55 28506962-5 2017 db/db mice, a widely used model of insulin-resistant diabetes and obesity, were either pair fed or treated with the Sglt inhibitor phloridzin, the insulin-sensitizer rosiglitazone, or insulin. Rosiglitazone 166-179 insulin Homo sapiens 147-154 28337819-8 2017 Moreover, insulin-sensitizing drugs (metformin, pioglitazone, and rosiglitazone) suppress LPS-induced TGF-beta and TNF-alpha mRNA expression in PFMC. Rosiglitazone 66-79 insulin Homo sapiens 10-17 26998551-8 2016 As proof of concept, rosiglitazone maleate (RSM), an insulin-sensitizing agent, was doped into the MSN to form a multifunctional MSN (RSM@MSN-ALC-BA-Ins), integrating with double-drugs loading, glucose-responsive performance, and real-time monitoring capability. Rosiglitazone 21-42 insulin Homo sapiens 53-60 27620069-3 2016 Although Thiazolidinediones (TZDs) such as rosiglitazone and pioglitazone are outstanding insulin sensitizers and are in clinical use since 1990s, however, their serious side effects such as heart attack and bladder cancer have limited their utilization. Rosiglitazone 43-56 insulin Homo sapiens 90-97 27268145-2 2016 Rosiglitazone (RGZ) and other thiazolidinedione (TZD) synthetic ligands of PPARgamma are insulin sensitizers that have been used for the treatment of type 2 diabetes. Rosiglitazone 0-13 insulin Homo sapiens 89-96 26317056-0 2014 Amelioration of insulin resistance by rosiglitazone is associated with increased adipose cell size in obese type 2 diabetic patients. Rosiglitazone 38-51 insulin Homo sapiens 16-23 26548081-4 2015 In the present study, we explored the binding interactions of antidiabetic drugs i.e., sulfonylurea drugs (glimepiride, glipizide, glyburide) and rapid acting insulin secretagogues viz., nateglinide, repaglinide and rosiglitazone; and Pgp inhibitors i.e., Generation I (verapamil and tamoxifen), III (tetradrine and tariquidar), and natural inhibitors (fumagillin and piperine) in mouse Pgp model. Rosiglitazone 216-229 insulin Homo sapiens 159-166 25621136-2 2015 However, theoretically adding rosiglitazone to insulin could help insulin to decrease the glucose level. Rosiglitazone 30-43 insulin Homo sapiens 66-73 25621136-11 2015 CONCLUSIONS: Rosiglitazone could help type 2 diabetes patients with poorly controlled glucose with insulin therapy to decrease glucose levels and reduce their daily insulin dose, but at the cost of increased total cholesterol level, hypoglycemia and edema risk. Rosiglitazone 13-26 insulin Homo sapiens 99-106 25621136-11 2015 CONCLUSIONS: Rosiglitazone could help type 2 diabetes patients with poorly controlled glucose with insulin therapy to decrease glucose levels and reduce their daily insulin dose, but at the cost of increased total cholesterol level, hypoglycemia and edema risk. Rosiglitazone 13-26 insulin Homo sapiens 165-172 25789586-0 2015 Damage to vascular endothelial cells by high insulin levels is associated with increased expression of ChemR23, and attenuated by PPAR-gamma agonist, rosiglitazone. Rosiglitazone 150-163 insulin Homo sapiens 45-52 26317056-4 2014 We did a longitudinal study with T2D patients treated with the insulin-sensitizer rosiglitazone to test the hypothesis that improved insulin sensitivity is associated with increased adipocyte size. Rosiglitazone 82-95 insulin Homo sapiens 133-140 26317056-7 2014 Rosiglitazone treatment ameliorated insulin resistance as evidenced by significantly decreased fasting plasma glucose and increased index of insulin sensitivity, QUICKI. Rosiglitazone 0-13 insulin Homo sapiens 36-43 26317056-7 2014 Rosiglitazone treatment ameliorated insulin resistance as evidenced by significantly decreased fasting plasma glucose and increased index of insulin sensitivity, QUICKI. Rosiglitazone 0-13 insulin Homo sapiens 141-148 26317056-9 2014 We conclude rosiglitazone treatment both enlarges existing large adipose cells and recruits new small adipose cells in T2D patients, improving fat storage capacity in adipose tissue and thus systemic insulin sensitivity. Rosiglitazone 12-25 insulin Homo sapiens 200-207 24622797-7 2014 Rosiglitazone treatment significantly improved a number of metabolic parameters of the ASKO mice, including insulin sensitivity. Rosiglitazone 0-13 insulin Homo sapiens 108-115 24636967-13 2014 Furthermore, metformin and rosiglitazone improved insulin resistance, while aripiprazole, metformin, and sibutramine decreased blood lipids. Rosiglitazone 27-40 insulin Homo sapiens 50-57